NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

細胞治療藥物製造市場:第 4 版

Cell Therapy Manufacturing Market (4th edition) by Type of Cell Manufactured (Immune Cells, Stem Cells and Others), Source of Cell (Autologous and Allogeneic), Scale of Operation (Preclinical, Clinical and Commercial),

出版商 Roots Analysis 商品編碼 1009627
出版日期 內容資訊 英文 550 Pages
商品交期: 最快1-2個工作天內
價格
如有價格方面的疑問請按下「詢問」鍵來信查詢
細胞治療藥物製造市場:第 4 版 Cell Therapy Manufacturing Market (4th edition) by Type of Cell Manufactured (Immune Cells, Stem Cells and Others), Source of Cell (Autologous and Allogeneic), Scale of Operation (Preclinical, Clinical and Commercial),
出版日期: 2021年05月01日內容資訊: 英文 550 Pages
簡介

細胞療法的成本取決於多種因素,包括製造時間、基於載體的細胞轉染和基因改造的程度。已發現此類產品的價格在 2,000 美元(軟骨植入物)和 50,000-60,000 美元(細胞和基因治療)之間波動。

細胞治療藥物製造服務是行業公司的混合體,例如歷史悠久的公司、中型公司、初創公司/中小企業和一些學術機構。值得注意的是,具有生產所需細胞療法所需能力和設備的創新者也提供外包服務。專業服務行業在過去幾年建立了重要的合作夥伴關係,幾家公司被大公司收購,目的是發展和加強他們在該領域的能力。隨著利益相關者努力減輕現有挑戰並專注於創新以改進電池生產工藝,預計市場將在中長期內顯著增長。

本報告調查和分析全球細胞治療製造市場,並提供有關當前市場狀況和未來機會的系統信息。

目錄

第 1 章前言

第 2 章執行摘要

第 3 章介紹

第 4 章市場概覽

  • 章節概述
  • 細胞治療藥物製造(業界公司):整體市場情況
  • 細胞治療藥物製造(非業界公司):整體市場情況

第 5 章監管情況

  • 章節概述
  • 當前場景
  • 細胞治療藥物製造監管認證
  • 細胞療法臨床階段製造指南總結
  • 與細胞療法臨床階段製造相關的現有挑戰

第 6 章克服挑戰的路線圖

  • 章節概述
  • 美國路線圖
  • 其他地區的路線圖

第 7 章細胞治療藥物製造自動化技術

  • 章節概述
  • 細胞治療藥物製造過程的自動化
  • 增長動力和障礙
  • 案例研究
  • GMP認證
  • 自動化/閉細胞療法藥物處理系統列表
  • 手動/自動化流程的比較分析

第 8 章簡介:行業公司

  • 章節概述
  • 北美服務提供商
    • Cognate BioServices
    • KBI Biopharma
    • Waisman Biomanufacturing
  • 歐洲服務提供商
    • BioNTech Innovative Manufacturing Services
    • Cell and Gene Therapy Catapult
    • Lonza
    • Roslin Cell Therapies
  • 亞太服務提供商
    • Cell Therapies
    • FUJIFILM Cellular Dynamics
    • Minaris Regenerative Medicine
    • MEDINET
    • Nikon CeLL Innovation
    • WuXi AppTec

第 9 章簡介:非工業公司

  • 章節概述
  • Center for Cell and Gene Therapy, Baylor College of Medicine
  • Centre for Cell Manufacturing Ireland, National University of Ireland
  • Clinical Cell and Vaccine Production Facility, University of Pennsylvania
  • Guy's and St. Thomas' GMP Facility, Guy's Hospital
  • Laboratory for Cell and Gene Medicine, Stanford University
  • Molecular and Cellular Therapeutics, University of Minnesota
  • Newcastle Advanced Therapies, Newcastle University
  • Rayne Cell Therapy Suite, King's College London
  • Scottish National Blood Transfusion Services Cellular Therapy Facility, Scottish Centre for Regenerative Medicine
  • Sydney Cell and Gene Therapy

第 10 章非營利組織的作用

  • 章節概述
  • 細胞治療藥物製造:非營利組織
  • 細胞治療藥物製造:國際社會

第 11 章合作

第 12 章設施擴建

第 13 章各大藥企的舉措

  • 章節概述
  • 主要製藥公司專注於細胞治療藥物製造的舉措清單
  • 主要製藥公司的競爭對標

第 14 章產能分析

第 15 章需求分析

第 16 章成本分析

第 17 章決策與採購決策框架

第 18 章市場規模和機會分析

  • 章節概述
  • 預測範圍
  • 輸入數據和關鍵先決條件
  • 預測方法
  • 全球細胞治療藥物製造市場
  • 細胞療法商業化生產的市場機遇
  • 細胞療法臨床規模製造的市場機遇

第 19 章主要考慮

第 20 章SWOT分析

第 21 章結論

第 22 章調查分析

第 23 章採訪實錄

第 24 章附錄1:表格數據

第 25 章附錄 2:公司/組織名單

目錄

Title:
Cell Therapy Manufacturing Market (4th edition)
by Type of Cell Manufactured (Immune Cells, Stem Cells and Others), Source of Cell (Autologous and Allogeneic), Scale of Operation (Preclinical, Clinical and Commercial), Purpose of Manufacturing (In-house and Contract) and Key Geographical Regions (North America, Europe, Asia-Pacific, Latin America and MENA) - Industry Trends and Global Forecasts, 2021-2030.

Overview:

The cost of cell-based therapies depends on various factors, such as duration of manufacturing, vector-based cell transfection and extent of gene modification. Price of such products has been observed to vary between USD 2,000 (for cartilage implants) to USD 50,000-60,000 (for cell and gene therapies). -- CEO, a small-sized cell therapies manufacturer.

Given the consistent increase in number of cell therapies being developed and launched, this upcoming therapeutic segment is on its way to becoming one of the highest valued markets within the biopharmaceutical industry. In fact, in February 2021, the USFDA approved Breyanzi®, a CAR-T cell-based therapy, developed by Bristol Myers Squibb, which is designed to treat relapsed or refractory large B-cell lymphoma. According to a recent report (published by The Alliance for Regenerative Medicine) , over 1,200 clinical trials, focused on the evaluation of cell therapies, gene therapies and tissue-based therapies, are currently being conducted by over 1,000 organizations (including academic institutions), worldwide. Further growth of the market is primarily hindered by the limited availability of expertise, lack of specialized infrastructure to produce cell therapies, and several product development and manufacturing related challenges.

With a sufficient body of evidence, validating the clinical benefits / therapeutic potential of this complex class of biologic drugs, the focus of stakeholders in this industry segment has now shifted to optimizing the cell therapy manufacturing process. Moreover, as more big pharma players enter this field of research, there is likely to be a substantial rise in the cell therapy manufacturing demand, as the proprietary product candidates of these large companies mature and need to be mass produced. In order to address the concerns related to manufacturing, several cell therapy developers (including the larger companies) have turned to contract manufacturing organizations (CMOs).

The cell therapy manufacturing service landscape features a mix of industry players (including well-established companies, mid-sized firms and start-ups / small companies), as well as several academic institutes. It is worth highlighting that innovator companies that have the required capabilities and facilities to produce cell therapies for in-house requirements, also offer contract services (primarily to ensure the optimum use of their resources and open up additional revenue generation opportunities) . Further, in order to make cell therapies more affordable, several stakeholders are integrating various degrees of automation to cut down on labor costs and also improve process scalability. This specialty services industry has witnessed significant partnership activity over the past few years, with several companies being acquired by the larger firms, in efforts to grow and consolidate their capabilities in this space. As stakeholders strive to mitigate existing challenges and focus on innovation to improve the cell production process, we believe that the market will witness significant growth in mid-long term.

Scope of the Report:

The "Cell Therapy Manufacturing Market (4th Edition) by Type of Cell Manufactured (Immune Cells, Stem Cells and Others ), Source of Cell (Autologous and Allogeneic), Scale of Operation (Preclinical, Clinical and Commercial), Purpose of Manufacturing (In-house and Contract) and Key Geographical Regions (North America, Europe, Asia-Pacific, Latin America and MENA) - Industry Trends and Global Forecasts, 2021-2030" report features an extensive study of the current market landscape and future opportunities associated with cell therapy manufacturing, along with information on both contract manufacturers, as well as developers having in-house production capabilities, offering in-depth analyses of the various business entities engaged in this domain, across key global regions. Amongst other elements, the report includes:

  • A detailed review of the overall landscape of players engaged in the manufacturing of cell-based therapies, along with information on type of cell manufactured (including immune cells (including T cells, dendritic cells, NK cells) , stem cells (including adult stem cells, human embryonic stem cells and induced pluripotent stem cells) and others), source of cell (autologous and allogeneic) , scale of operation (preclinical, clinical and commercial) , purpose of production (fulfilling in-house requirements and contract services) , manufacturing capabilities / services offered (including R&D, cell culture development, quality testing, packaging, cell banking, supply chain management services, and regulatory services) , as well as location of headquarters and their respective manufacturing facilities.
  • An analysis of the various expansion initiatives undertaken by service providers engaged in this domain in order to augment their respective cell therapy manufacturing capabilities, during the period 2016-2021, based on several relevant parameters, such as year of expansion, type of cell manufactured, scale of operation, purpose of expansion (facility expansion and new facility) , location of expanded manufacturing facility, and most active players (in terms of number of expansion initiatives undertaken) .
  • An analysis of the recent partnerships focused on the manufacturing of cell-based therapies, which have been established during the period 2016-2021, based on several relevant parameters, such as the year of agreement, type of partnership model adopted, type of cell and scale of operation.
  • A review of the various cell therapy manufacturing initiatives undertaken by big pharma players engaged in this domain, based on several relevant parameters, such as number of initiatives, year of initiative, purpose of initiative, type of initiative, scale of operation and type of cell manufactured.
  • Informed estimates of the annual commercial and clinical demand for cell therapies (in terms of number of patients), based on type of cell therapy and key geographical regions.
  • An estimate of the overall, installed capacity for the manufacturing of cell-based therapies, based on information reported by various industry stakeholders in the public domain, highlighting the distribution of the available capacity on the basis of scale of operation (clinical and commercial), company size (small, mid-sized and large firms) and key geographical regions (North America, Europe and Asia Pacific) .
  • An in-depth analysis of cell therapy manufacturers using three versatile representations, namely [A] a three dimensional grid analysis, presenting the distribution of companies on the basis of type of cell manufactured, scale of operation and purpose of production, [B] a logo landscape, based on the type of cell manufactured, geographical location of manufacturer (North America, Europe and Asia Pacific) , and type and size of organization (non-industry players, and small, mid-sized and large companies) , and [C] a schematic world map representation, highlighting the geographical location of cell therapy manufacturing facilities of both industry and non-industry stakeholders.
  • A detailed analysis of various factors that are likely to influence the price of cell-based therapies, featuring different models / approaches adopted by manufacturers while determining the price of their proprietary offerings.
  • An elaborate discussion on the role of automation technologies in improving the current manufacturing methods, along with a comparative (qualitive) analysis of cost differences between manual and automated processes.
  • A qualitative analysis, highlighting the various factors that need to be taken into consideration by cell therapy developers, while deciding whether to manufacture their respective products in-house or engage the services of a CMO.
  • A discussion on cell therapy manufacturing regulations across various geographies, including North America (focusing on the US) , Europe and Asia (focusing on Japan and China) , featuring an analysis of the diverse certifications / accreditations awarded to manufacturing facilities by important regulatory bodies across the globe.
  • Elaborate profiles of key players (industry and non-industry) that offer contract manufacturing services for cell-based therapies; each profile includes an overview of the company / organization, information on its manufacturing facilities, service portfolio, recent partnerships and an informed future outlook.
  • A discussion on affiliated trends, key drivers and challenges, which are likely to impact the industry's evolution, under an elaborate SWOT framework, along with a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall market dynamics.
  • Insights generated in a market-wide survey, featuring inputs solicited from experts who are directly / indirectly involved in the development and / or manufacturing of cell-based therapies.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the cell therapy manufacturing market. Based on parameters, such as number of ongoing / planned clinical studies, cell therapy manufacturing costs, target patient population, and anticipated adoption of such products, we have provided informed estimates on the evolution of the market in the short to mid-term and mid to long term, for the period 2021-2030. The report also features the likely distribution of the current and forecasted opportunity across [A] type of cell therapy (T cell therapies,dendritic and tumor cell therapies, NK cell therapies, stem cell therapies and others) , [B] source of cell (autologous and allogeneic) , [C] scale of operation (clinical and commercial) , [D] purpose of manufacturing (in-house and contract) , and [E] key geographical regions (North America, Europe, Asia Pacific, Latin America and MENA) . In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth.

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals:

  • Troels Jordansen (Chief Executive Officer, Glycostem Therapeutics)
  • Gilles Devillers (General Manager, Bio Elpida)
  • Wei (William) Cao (Chief Executive Officer, Gracell Biotechnologies)
  • Arik Hasson (Executive VP Research and Development, Kadimastem)
  • Fiona Bellot (Business Development Manager, Roslin CT)
  • David Mckenna (Professor and American Red Cross Chair in Transfusion Medicine, University of Minnesota)
  • Victor Lietao Li (Co-Founder and Chief Executive Officer, Lion TCR)
  • Arnaud Deladeriere (Manager, Business Development & Operations-cGMP Manufacturing Unit, C3i Center for Commercialization of Cancer Immunotherapy)
  • Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing)
  • Mathilde Girard (Department Leader, Cell Therapy Innovation and Development, Yposkesi)Tim Oldham (Chief Executive Officer, Cell Therapies)
  • Gerard MJ Bos (Chief Executive Officer, CiMaas)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered:

  • What is the current, annual, global demand for cell-based therapies? How is the demand for such products likely to evolve over the next decade?
  • What is the current, installed contract manufacturing capacity for cell therapies?
  • What are the key parameters governing the price of cell therapies?
  • What are the key recent developments (such as partnerships and expansions) in this industry?
  • What kind of partnership models are commonly adopted by stakeholders engaged in this domain?
  • What are the different initiatives undertaken by big pharma players for the manufacturing of cell therapies in the recent past?
  • What different types of automated technology platforms available for the development and manufacturing of cell therapies?
  • Who are the key players (industry / non-industry) engaged in the manufacturing of cell-based therapies across the world?
  • What are the key factors influencing the make (manufacture in-house) versus buy (outsource) decision related to cell therapies?
  • How is the current and future market opportunity likely to be distributed across key market segments?

Chapter Outline:

Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of the cell-based therapy manufacturing market and its likely evolution in the short to mid-term, and long term.

Chapter 3 provides a general introduction to cell-based therapies and ATMPs. It further includes a detailed discussion on the manufacturing process of cell-based therapies, and associated challenges, along with highlighting the applications of currently approved products. Additionally, it highlights information on the different manufacturing models (centralized and decentralized) that are being used for the production of cell-based therapies, as well as their associated advantages and disadvantages. Furthermore, it features details related to the scalability of cell-based therapies. The chapter also includes a brief overview of the role of automation and the need for effective supply chain management for cell-based therapies.

Chapter 4 features a detailed list of all the industry, as well as non-industry players that are actively involved in the manufacturing of cell-based therapies. It provides information on the type of cell manufactured (including immune cells (including T cells, dendritic cells, NK cells) , stem cells (including adult stem cells, human embryonic stem cells and induced pluripotent stem cells) and others), source of cell (autologous and allogeneic) , scale of operation (preclinical, clinical and commercial) , purpose of production (fulfilling in-house requirements and contract services) , manufacturing capabilities / services offered (including R&D, cell culture development, quality testing, packaging, cell banking, supply chain management services, and regulatory services) , as well as location of headquarters and their respective manufacturing facilities.

Chapter 5 features a detailed discussion on the regulatory landscape related to cell therapies across various geographies, such as the US, Europe, Japan and China. Further, it presents an analysis of the manufacturing facilities on basis of the certifications awarded (for manufacturing cell-based therapies) to individual sites by various regulatory bodies across the globe.

Chapter 6 describes the strategies that are likely to be adopted to accelerate the translation of cell-based therapies from laboratory to clinics. It provides details on roadmaps published by different organizations located across various geographies, specifically in the US.

Chapter 7 discusses the role of automation technologies in optimization of current manufacturing practices with the use of closed and single use systems. Further, it features a roadmap that provides information on the steps to develop automation devices, supported by two case studies. It also presents a qualitive analysis on the cost incurred while manufacturing cell-based therapies using manual versus automated manufacturing approaches. In addition, it features a list of organizations that offer automated technologies for manufacturing operations or provide services to therapy developers to automate their production processes.

Chapter 8 features detailed profiles of industry players that offer contract manufacturing services for cell therapies at the clinical and / or commercial scales. Each profile provides a brief overview of the company, details on its manufacturing capabilities and facilities, recent partnerships and an informed future outlook.

Chapter 9 features profiles of non-industry players that offer contract manufacturing services for cell therapies. Each profile provides a brief overview of the organization, and details on its service portfolio and manufacturing facilities.

Chapter 10 discusses the role of non-profit organizations in this domain. It provides a list of organizations that are actively involved in the development and production of cell-based therapies, across different global regions. Further, it includes profiles of organizations that provide financial and / or technological support to cell therapy manufacturers and developers. Additionally, the chapter provides information on various international / national societies that help in disseminating knowledge about the advancement of these therapies to the general community.

Chapter 11 features an analysis of the various partnerships and collaborations that have been inked amongst players engaged in this domain, between 2016-2021 (till February) . It includes a brief description on the various types of partnership models that are employed by stakeholders in this market, and an analysis on the trend of partnerships. It also includes analyses based on year of agreement, type of partnership, scale of operation, type of cell manufactured and most active players. Moreover, it presents a schematic world map representation of the geographical distribution of this activity, highlighting inter- and intracontinental deals. Further, the chapter features an analysis of the various acquisitions that have taken place in this domain, highlighting geographical activity. The analysis also features an ownership change matrix, providing insights on the involvement of private and public sector entities in this domain.

Chapter 12 presents detailed analysis on the expansions that have taken place in the cell therapy manufacturing industry, since 2016. It includes information on expansions carried out for increasing existing capabilities, as well as those intended for setting-up of new facilities by manufacturers engaged in this domain. The expansion instances were analyzed based on various parameters, including year of expansion, type of cell manufactured, scale of operation, purpose of expansion (facility expansion and new facility) , location of expanded manufacturing facility, and most active players (in terms of number of expansion initiatives undertaken) .

Chapter 13 provides a detailed analysis of the various cell therapy manufacturing initiatives undertaken by big pharma players engaged in this domain, based on several relevant parameters, such as number of initiatives, year of initiative, purpose of initiative, type of initiative, scale of operation and type of cell manufactured.

Chapter 14 features a comprehensive analysis of the overall installed capacity of cell-based therapy manufacturers. The analysis is based on meticulous data collection of reported capacities, via both secondary and primary research, of various small, mid-sized and large companies, and non-industry players distributed across their respective facilities. The results of this analysis were used to establish an informed opinion on the cell-based therapy production capabilities of organizations across different types of organization (industry and non-industry) , scale of operation (clinical and commercial) , geographies (North America, Europe and Asia Pacific) and company size (small, mid-sized and large organizations) .

Chapter 15 features a detailed analysis of the annual demand for cell therapies (in terms of number of patients) , considering various relevant parameters, such as target patient population, dosing frequency and dose strength of the approved cell therapies, as well as those therapies that are currently being evaluated in clinical trials. The demand analysis has been segmented across different types of cell therapies (including CAR-T cells, TCR cells, TIL cells, NK cells, dendritic cells, tumor cells and stem cells) , scale of operation (clinical and commercial) and regions (North America, Europe and Asia Pacific) .

Chapter 16 highlights our views on various factors, including manufacturing costs, that may be taken into consideration while pricing cell-based therapies. It features discussions on different pricing models / approaches adopted by manufacturers to decide the price of its proprietary products.

Chapter 17 presents a qualitative analysis that highlights the various factors that need to be taken into consideration by cell therapy developers while deciding whether to manufacture their respective products in-house or engage the services of a CMO.

Chapter 18 presents an elaborate market forecast analysis, highlighting the future potential of the market till the year 2030. The chapter presents a detailed market segmentation on the basis of [A] type of cell therapy (T cell therapies, dendritic and tumor cell therapies, NK cell therapies, stem cell therapies and others) , [B] source of cell (autologous and allogeneic) , [C] scale of operation (clinical and commercial) , [D] purpose of manufacturing (in-house and contract) , and [E] key geographical regions (North America, Europe, Asia Pacific and Latin America and MENA) .

Chapter 19 presents a collection of key insights derived from the study. It includes a grid analysis, highlighting the distribution of cell-based therapy manufacturers on the basis of type of cell manufactured, scale of operation and purpose of production (fulfilling in-house requirement / contract service provider). In addition, it consists of two logo landscapes, representing the distribution of cell-based therapy manufacturers based on the type of cell manufactured (immune cells and stem cells), geographical regions (North America, Europe and Asia Pacific) and the type / size of organization (non-industry, small, mid-sized and large companies) . The chapter also comprises of two schematic world map representations to highlight the locations of various cell-based therapy manufacturing facilities across different continents.

Chapter 20 provides a discussion on affiliated trends, key drivers and challenges, under an elaborate SWOT framework, featuring a Harvey ball analysis, highlighting the relative impact of each SWOT parameter on the overall cell therapy manufacturing industry.

Chapter 21 summarizes the overall report, wherein we have mentioned all the key facts and figures described in the previous chapters. The chapter also highlights important evolutionary trends that were identified during the course of the study and are expected to influence the future of the cell therapy manufacturing market.

Chapter 22 presents insights from the survey conducted for this study. We invited over 100 stakeholders involved in the development and / or manufacturing of different types of cell therapies. The participants, who were primarily Director / CXO level representatives of their respective companies, helped us develop a deeper understanding on the nature of their services and the associated commercial potential.

Chapter 23 is a collection of interview transcripts of the discussions held with key stakeholders in the industry. We have presented details of interviews held with Troels Jordansen (Chief Executive Officer, Glycostem Therapeutics), Gilles Devillers (General Manager, Bio Elpida), Wei (William) Cao (Chief Executive Officer, Gracell Biotechnologies), Arik Hasson (Executive VP Research and Development, Kadimastem), Fiona Bellot (Business Development Manager, Roslin CT), David Mckenna (Professor and American Red Cross Chair in Transfusion Medicine, University of Minnesota), Victor Lietao Li (Co-Founder and Chief Executive Officer, Lion TCR), Arnaud Deladeriere (Manager, Business Development & Operations-cGMP Manufacturing Unit, C3i Center for Commercialization of Cancer Immunotherapy), Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing), Mathilde Girard (Department Leader, Cell Therapy Innovation and Development, Yposkesi), Tim Oldham (Chief Executive Officer, Cell Therapies) and Gerard MJ Bos (Chief Executive Officer, CiMaas).

Chapter 24 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 25 is an appendix, which contains a list of companies and organizations mentioned in this report.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Key Questions Answered
  • 1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Context and Background
  • 3.2. Introduction to Cell-based Therapies
    • 3.2.1. Comparison of Cell-based Therapies and Other Biotechnology Products
    • 3.2.2. Classification of Advanced Therapy Medicinal Products (ATMPs)
    • 3.2.3. Current Market Landscape of ATMPs
  • 3.3. Overview of Cell Therapy Manufacturing
  • 3.4. Cell Therapy Manufacturing Models
    • 3.4.1. Centralized Manufacturing
    • 3.4.2. Decentralized Manufacturing
  • 3.5. Scalability of Cell Therapy Manufacturing Processes
    • 3.5.1. Scale-up
    • 3.5.2. Scale-out
  • 3.6. Types of Cell Therapy Manufacturers
  • 3.7. Key Challenges Associated with Manufacturing of Cell Therapies
  • 3.8. Factors Influencing Cell Therapy Manufacturing
  • 3.9. Automation of Cell Therapy Manufacturing Processes
  • 3.10. Cell Therapy Manufacturing Supply Chain
  • 3.11. Future Perspectives

4. MARKET OVERVIEW

  • 4.1. Chapter Overview
  • 4.2. Cell Therapy Manufacturing (Industry Players): Overall Market Landscape
    • 4.2.1. Analysis by Company Size
    • 4.2.2. Analysis by Year of Establishment
    • 4.2.3. Analysis by Location of Headquarters
    • 4.2.4. Analysis by Location of Manufacturing Facility
    • 4.2.5. Analysis by Type of Manufacturer
    • 4.2.6. Analysis by Type of Cell Manufactured
    • 4.2.7. Analysis by Source of Cells
    • 4.2.8. Analysis by Scale of Operation
    • 4.2.9. Analysis by Manufacturing Capabilities / Services Offered
  • 4.3. Cell Therapy Manufacturing (Non-Industry Players): Overall Market Landscape
    • 4.3.1. Analysis by Location of Headquarters
    • 4.3.2. Analysis by Location of Manufacturing Facility
    • 4.3.3. Analysis by Type of Manufacturer
    • 4.3.4. Analysis by Type of Cell Manufactured
    • 4.3.5. Analysis by Source of Cells
    • 4.3.6. Analysis by Scale of Operation
    • 4.3.7. Analysis by Manufacturing Capabilities / Services Offered

5. REGULATORY LANDSCAPE

  • 5.1. Chapter Overview
  • 5.2. Current Scenario
    • 5.2.1. Regulatory Guidelines in North America
    • 5.2.2. Regulatory Guidelines in Europe
    • 5.2.3. Regulatory Guidelines in Japan
    • 5.2.4. Regulatory Guidelines in China
    • 5.2.5. Conditional Approvals
  • 5.3. Regulatory Accreditations for Cell Therapy Manufacturing
    • 5.3.1. Facilities Approved by Regulators for Cell Therapy Manufacturing
  • 5.4. Summary of Guidelines for Clinical-stage Manufacturing of Cell Therapies
  • 5.5. Existing Challenges Associated with Clinical-stage Manufacturing of Cell Therapies
    • 5.5.1. Variability in Regulatory Guidelines Established across Different Geographies

6. ROADMAPS FOR OVERCOMING CHALLENGES

  • 6.1. Chapter Overview
  • 6.2. Roadmap for the US
    • 6.2.1. Cell Processing
    • 6.2.2. Cell Preservation, Distribution and Handling
    • 6.2.3. Process Automation and Data Analytics
    • 6.2.4. Process Monitoring and Quality Control
    • 6.2.5. Standardization and Regulatory Support
    • 6.2.6. Workforce Development
    • 6.2.7. Supply Chain and Logistics
  • 6.3. Roadmaps for Other Geographies
    • 6.3.1. Europe
    • 6.3.2. Asia Pacific

7. AUTOMATION TECHNOLOGIES FOR CELL THERAPY MANUFACTURING

  • 7.1. Chapter Overview
  • 7.2. Automation of Cell Therapy Manufacturing Processes
    • 7.2.1. Closed Systems
    • 7.2.2. Single-use Systems
    • 7.2.3. Modular Systems
  • 7.3. Growth Drivers and Roadblocks
  • 7.4. Case Studies
    • 7.4.1. Roadmap for Developing an Automated Cell Manufacturing / Processing Device
    • 7.4.2. Automating the Cell Therapy Manufacturing Process
  • 7.5. GMP-in-a-Box
  • 7.6. List of Automated and Closed Cell Therapy Processing Systems
  • 7.7. Comparative Analysis of Manual and Automated Processes

8. PROFILES: INDUSTRY PLAYERS

  • 8.1. Chapter Overview
  • 8.2. Service Providers in North America
    • 8.2.1 Cognate BioServices
      • 8.2.1.1. Company Overview
      • 8.2.1.2. Service Portfolio
      • 8.2.1.3. Manufacturing Facilities and Capabilities
      • 8.2.1.4. Partnerships
      • 8.2.1.5. Future Outlook
    • 8.2.2. KBI Biopharma
      • 8.2.2.1. Company Overview
      • 8.2.2.2. Service Portfolio
      • 8.2.2.3. Manufacturing Facilities and Capabilities
      • 8.2.2.4. Partnerships
      • 8.2.2.5. Future Outlook
    • 8.2.3. Waisman Biomanufacturing
      • 8.2.3.1. Company Overview
      • 8.2.3.2. Service Portfolio
      • 8.2.3.3. Manufacturing Facilities and Capabilities
      • 8.2.3.4. Partnerships
      • 8.2.3.5. Future Outlook
  • 8.3. Service Providers in Europe
    • 8.3.1. BioNTech Innovative Manufacturing Services
      • 8.3.1.1. Company Overview
      • 8.3.1.2. Service Portfolio
      • 8.3.1.3. Manufacturing Facilities and Capabilities
      • 8.3.1.4. Partnerships
      • 8.3.1.5. Future Outlook
    • 8.3.2. Cell and Gene Therapy Catapult
      • 8.3.2.1. Company Overview
      • 8.3.2.2. Service Portfolio
      • 8.3.2.3. Manufacturing Facilities and Capabilities
      • 8.3.2.4. Partnerships
      • 8.3.2.5. Future Outlook
    • 8.3.3. Lonza
      • 8.3.3.1. Company Overview
      • 8.3.3.2. Service Portfolio
      • 8.3.3.3. Manufacturing Facilities and Capabilities
      • 8.3.3.4. Partnerships
      • 8.3.3.5. Future Outlook
    • 8.3.4. Roslin Cell Therapies
      • 8.3.4.1. Company Overview
      • 8.3.4.2. Service Portfolio
      • 8.3.4.3. Manufacturing Facilities and Capabilities
      • 8.3.4.4. Partnerships
      • 8.3.4.5. Future Outlook
  • 8.4. Service Providers in Asia Pacific
    • 8.4.1. Cell Therapies
      • 8.4.1.1. Company Overview
      • 8.4.1.2. Service Portfolio
      • 8.4.1.3. Manufacturing Facilities and Capabilities
      • 8.4.1.4. Partnerships
      • 8.4.1.5. Future Outlook
    • 8.4.2. FUJIFILM Cellular Dynamics
      • 8.4.2.1. Company Overview
      • 8.4.2.2. Service Portfolio
      • 8.4.2.3. Manufacturing Facilities and Capabilities
      • 8.4.2.4. Partnerships
      • 8.4.2.5. Future Outlook
    • 8.4.3. Minaris Regenerative Medicine
      • 8.4.3.1. Company Overview
      • 8.4.3.2. Service Portfolio
      • 8.4.3.3. Manufacturing Facilities and Capabilities
      • 8.4.3.4. Partnerships
      • 8.4.3.5. Future Outlook
    • 8.4.4. MEDINET
      • 8.4.4.1. Company Overview
      • 8.4.4.2. Service Portfolio
      • 8.4.4.3. Manufacturing Facilities and Capabilities
      • 8.4.4.4. Partnerships
      • 8.4.4.5. Future Outlook
    • 8.4.5. Nikon CeLL Innovation
      • 8.4.5.1. Company Overview
      • 8.4.5.2. Service Portfolio
      • 8.4.5.3. Manufacturing Facilities and Capabilities
      • 8.4.5.4. Partnerships
      • 8.4.5.5. Future Outlook
    • 8.4.6. WuXi AppTec
      • 8.4.6.1. Company Overview
      • 8.4.6.2. Service Portfolio
      • 8.4.6.3. Manufacturing Facilities and Capabilities
      • 8.4.6.4. Partnerships
      • 8.4.6.5. Future Outlook

9. PROFILES: NON-INDUSTRY PLAYERS

  • 9.1. Chapter Overview
  • 9.2. Center for Cell and Gene Therapy, Baylor College of Medicine
    • 9.2.1. Overview
    • 9.2.2. Operating Segments
    • 9.2.3. Service Portfolio
    • 9.2.4. Manufacturing Facilities and Capabilities
  • 9.3. Centre for Cell Manufacturing Ireland, National University of Ireland
    • 9.3.1. Overview
    • 9.3.2. Service Portfolio
    • 9.3.3. Manufacturing Facilities and Capabilities
  • 9.4. Clinical Cell and Vaccine Production Facility, University of Pennsylvania
    • 9.4.1. Overview
    • 9.4.2. Service Portfolio
    • 9.4.3. Manufacturing Facilities and Capabilities
  • 9.5. Guy's and St. Thomas' GMP Facility, Guy's Hospital
    • 9.5.1. Overview
    • 9.5.2. Service Portfolio
    • 9.5.3. Manufacturing Facilities and Capabilities
  • 9.6. Laboratory for Cell and Gene Medicine, Stanford University
    • 9.6.1. Overview
    • 9.6.2. Service Portfolio
    • 9.6.3. Manufacturing Facilities and Capabilities
  • 9.7. Molecular and Cellular Therapeutics, University of Minnesota
    • 9.7.1. Overview
    • 9.7.2. Service Portfolio
    • 9.7.3. Manufacturing Facilities and Capabilities
  • 9.8. Newcastle Advanced Therapies, Newcastle University
    • 9.8.1. Overview
    • 9.8.2. Service Portfolio
    • 9.8.3. Manufacturing Facilities and Capabilities
  • 9.9. Rayne Cell Therapy Suite, King's College London
    • 9.9.1. Overview
    • 9.9.2. Manufacturing Facilities and Capabilities
  • 9.10. Scottish National Blood Transfusion Services Cellular Therapy Facility, Scottish Centre for Regenerative Medicine
    • 9.10.1. Overview
    • 9.10.2. Manufacturing Facilities and Capabilities
  • 9.11. Sydney Cell and Gene Therapy
    • 9.11.1. Overview
    • 9.11.2. Manufacturing Facilities and Capabilities

10. ROLE OF NON-PROFIT ORGANIZATIONS

  • 10.1. Chapter Overview
  • 10.2. Cell Therapy Manufacturing: Non-Profit Organizations
    • 10.2.1. CellCAN
    • 10.2.2. Cell Therapy Manufacturing Cooperative Research Center
    • 10.2.3. National Cell Manufacturing Consortium (NCMC)
    • 10.2.4. California Institute of Regenerative Medicine (CIRM)
  • 10.3. Cell Therapy Manufacturing: International Societies

11. PARTNERSHIPS

  • 11.1. Chapter Overview
  • 11.2. Partnership Models
  • 11.3. Cell Therapy Manufacturing: List of Partnerships
    • 11.3.1. Analysis by Year of Partnership
    • 11.3.2. Analysis by Type of Partnership
    • 11.3.3. Analysis by Year and Type of Partnership
  • 11.4. Analysis by Type of Cell
  • 11.5. Analysis by Scale of Operation
  • 11.6. Analysis by Region
    • 11.6.1. Country-wise Distribution
    • 11.6.2. Continent-wise Distribution
  • 11.7. Most Active Players: Analysis by Number of Partnerships
  • 11.8. Cell Therapy Manufacturing: List of Acquisitions
    • 11.8.1. Analysis by Year of Acquisition
    • 11.8.2. Analysis by Year of Acquisition and Type of Cell
    • 11.8.3. Analysis by Region
      • 11.8.3.1. Country-wise Distribution
      • 11.8.3.2. Continent-wise Distribution
    • 11.8.4. Ownership Change Matrix

12. FACILITY EXPANSIONS

  • 12.1. Chapter Overview
  • 12.2. Cell Therapy Manufacturing: List of Expansions
    • 12.2.1. Cumulative Year-wise Distribution
    • 12.2.2. Analysis by Purpose of Expansion
    • 12.2.3. Analysis by Types of Cells
    • 12.2.4. Analysis by Scale of Operation
    • 12.2.5. Analysis by Location of Manufacturing Facility
    • 12.2.6. Analysis by Purpose of Expansion and Region
    • 12.2.7. Most Active Players: Analysis by Number of Expansions
    • 12.2.8. Most Active Players: Analysis by Area of Expansion
    • 12.2.9. Analysis by Region and Area of Expansion

13. BIG PHARMA INITIATIVES

  • 13.1. Chapter Overview
  • 13.2. List of Cell Therapy Manufacturing Focused Initiatives of Big Pharma Players
    • 13.2.1. Analysis by Number of Initiatives
    • 13.2.2. Analysis by Year of Initiative
    • 13.2.3. Analysis by Purpose of Initiative
    • 13.2.4. Analysis by Type of Initiative
      • 13.2.4.1. Analysis by Type of Partnership
      • 13.2.4.2. Analysis by Type of Expansion
    • 13.2.5. Analysis by Scale of Operation
    • 13.2.6. Analysis by Types of Cells
    • 13.2.7. Analysis by Year of Initiative and Company
    • 13.2.8. Analysis by Purpose of Initiative and Company
    • 13.2.9. Analysis by Year and Type of Initiative
    • 13.2.10. Analysis by Region of Expansion and Company
    • 13.2.11. Analysis by Types of Cells and Company
  • 13.3. Competitive Benchmarking of Big Pharmaceutical Players
    • 13.3.1. Harvey Ball Analysis: Big Pharma Investment Summary

14. CAPACITY ANALYSIS

  • 14.1. Chapter Overview
  • 14.2. Key Assumptions and Methodology (Industry Players)
    • 14.2.1 Cell Therapy Manufacturing: Installed Global Capacity (Number of Cleanrooms)
      • 14.2.1.1. Analysis by Company Size
      • 14.2.1.2. Analysis by Scale of Operation
      • 14.2.1.3. Analysis by Location of Manufacturing Facility
      • 14.2.1.4. Analysis by Company Size and Geography
      • 14.2.1.5. Analysis by Scale of Operation and Geography
    • 14.2.2. Cell Therapy Manufacturing: Installed Global Capacity (Cleanroom Area)
      • 14.2.2.1. Analysis by Company Size
      • 14.2.2.2. Analysis by Scale of Operation
      • 14.2.2.3. Analysis by Location of Manufacturing Facility
      • 14.2.2.4. Analysis by Company Size and Geography
      • 14.2.2.5. Analysis by Scale of Operation and Geography
  • 14.3. Key Assumptions and Methodology (Non-Industry Players)
    • 14.3.1. Cell Therapy Manufacturing: Installed Global Capacity (Number of Cleanrooms)
      • 14.3.1.1. Analysis by Scale of Operation
      • 14.3.1.2. Analysis by Location of Manufacturing Facility
    • 14.3.2. Cell Therapy Manufacturing: Installed Global Capacity (Cleanroom Area)
      • 14.3.2.1. Analysis by Scale of Operation
      • 14.3.2.2. Analysis by Location of Manufacturing Facility
  • 14.4 Concluding Remarks

15. DEMAND ANALYSIS

  • 15.1 Chapter Overview
  • 15.2 Scope and Methodology
  • 15.3 Global Demand for Cell Therapy Manufacturing
  • 15.4 Global Clinical Demand for Cell Therapy Manufacturing
    • 15.4.1. Analysis by Type of Cell Therapy
    • 15.4.2. Analysis by Geographical Location
  • 15.5. Global Commercial Demand for Cell Therapy Manufacturing
    • 15.5.1. Analysis by Type of Cell Therapy
    • 15.5.2. Analysis by Geographical Location

16. COST PRICE ANALYSIS

  • 16.1. Chapter Overview
  • 16.2. Factors Contributing to the High Price of Cell Therapies
  • 16.3. Pricing Models for Cell Therapies
    • 16.3.1. Based on Associated Costs for T-cell Therapies
    • 16.3.2. Based on Associated Costs for Stem Cell Therapies
    • 16.3.3. Based on Availability of Competing Products
    • 16.3.4. Based on Target Patient Segment
    • 16.3.5. Based on the Opinions of Industry Experts
  • 16.4. Cell Therapy Cost Optimization
    • 16.4.1. Role of Cost of Goods Sold
    • 16.4.2. Role of Automation
  • 16.5. Role of Cell Therapy Contract Manufacturing Organizations
  • 16.6. Reimbursement-related Considerations for Cell Therapies
    • 16.6.1. Case Study: The National Institute for Health and Care Excellence's (NICE) Appraisal of CAR-T Therapies

17. MAKE VERSUS BUY DECISION MAKING FRAMEWORK

  • 17.1. Chapter Overview
  • 17.2. Assumptions and Key Parameters
  • 17.3. Cell Therapy Manufacturing: Make versus Buy Decision Making
    • 17.3.1. Scenario 1
    • 17.3.2. Scenario 2
    • 17.3.3. Scenario 3
    • 17.3.4. Scenario 4
  • 17.4. Concluding Remarks

18. MARKET SIZING AND OPPORTUNITY ANALYSIS

  • 18.1. Chapter Overview
  • 18.2. Scope of the Forecast
  • 18.3. Input Data and Key Assumptions
  • 18.4. Forecast Methodology
  • 18.5. Global Cell Therapy Manufacturing Market, 2021-2030
    • 18.5.1. Cell Therapy Manufacturing Market, 2021-2030: Distribution by Type of Cell Therapy
    • 18.5.2. Cell Therapy Manufacturing Market, 2021-2030: Distribution by Source of Cells
    • 18.5.3. Cell Therapy Manufacturing Market, 2021-2030: Distribution by Scale of Operation
    • 18.5.4. Cell Therapy Manufacturing Market, 2021-2030: Distribution by Purpose of Manufacturing
    • 18.5.5. Cell Therapy Manufacturing Market, 2021-2030: Distribution by Region
  • 18.6. Market Opportunity for Commercial Scale Manufacturing of Cell-based Therapies
    • 18.6.1. Global Commercial Scale Manufacturing Market for T-cell Therapies, 2021-2030
      • 18.6.1.1. Commercial Scale Manufacturing Market for T-cell Therapies, 2021-2030: Distribution by Type of Therapy
      • 18.6.1.2. Commercial Scale Manufacturing Market for T-cell Therapies, 2021-2030: Distribution by Source of Cells
      • 18.6.1.3. Commercial Scale Manufacturing Market for T-cell Therapies, 2021-2030: Distribution by Region
    • 18.6.2. Global Commercial Scale Manufacturing Market for NK Cell Therapies, 2021-2030
      • 18.6.2.1. Commercial Scale Manufacturing Market for NK Cell Therapies, 2021-2030: Distribution by Source of Cells
      • 18.6.2.2. Commercial Scale Manufacturing Market for NK Cell Therapies, 2021-2030: Distribution by Region
    • 18.6.3. Global Commercial Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies, 2021-2030
      • 18.6.3.1. Commercial Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies, 2021-2030: Distribution by Type of Therapy
      • 18.6.3.2. Commercial Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies, 2021-2030: Distribution by Region
    • 18.6.4. Global Commercial Scale Manufacturing Market for Stem Cell Therapies, 2021-2030
      • 18.6.4.1. Commercial Scale Manufacturing Market for Stem Cell Therapies, 2021-2030: Distribution by Source of Cells
      • 18.6.4.2. Commercial Scale Manufacturing Market for Stem Cell Therapies, 2021-2030: Distribution by Region
  • 18.7. Market Opportunity for Clinical Scale Manufacturing of Cell-based Therapies
    • 18.7.1. Global Clinical Scale Manufacturing Market for T-cell Therapies, 2021-2030
      • 18.7.1.1. Clinical Scale Manufacturing Market for T-cell Therapies, 2021-2030: Distribution by Type of Therapy
      • 18.7.1.2. Clinical Scale Manufacturing Market for T-cell Therapies, 2021-2030: Distribution by Source of Cells
      • 18.7.1.3. Clinical Scale Manufacturing Market for T-cell Therapies, 2021-2030: Distribution by Region
    • 18.7.2. Global Clinical Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies, 2021-2030
      • 18.7.2.1. Clinical Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies, 2021-2030: Distribution by Type of Therapy
      • 18.7.2.2. Clinical Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies, 2021-2030: Distribution by Source of Cells
      • 18.7.2.3. Clinical Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies, 2021-2030: Distribution by Region
    • 18.7.3. Global Clinical Scale Manufacturing Market for NK Cell Therapies, 2021-2030
      • 18.7.3.1. Clinical Scale Manufacturing Market for NK Cell Therapies, 2021-2030: Distribution by Source of Cells
      • 18.7.3.2. Clinical Scale Manufacturing Market for NK Cell Therapies, 2021-2030: Distribution by Region
    • 18.7.4. Global Clinical Scale Manufacturing Market for Stem Cell Therapies, 2021-2030
      • 18.7.4.1. Clinical Scale Manufacturing Market for Stem Cell Therapies, 2021-2030: Distribution by Source of Cells
      • 18.7.4.2. Clinical Scale Manufacturing Market for Stem Cell Therapies, 2021-2030: Distribution by Region

19. KEY INSIGHTS

  • 19.1. Chapter Overview
  • 19.2. Cell Therapy Manufacturing: Grid Analysis
  • 19.3. Cell Therapy Manufacturing: Logo Landscape
    • 19.3.1. Cell Therapy Manufacturing: Logo Landscape, Immune Cells
    • 19.3.2. Cell Therapy Manufacturing: Logo Landscape, Stem Cells
  • 19.4. Cell Therapy Manufacturing: World Map Representation based on Location of Manufacturing Facility
    • 19.4.1. Industry Players
    • 19.4.2. Non-Industry Players

20. SWOT ANALYSIS

  • 20.1. Chapter Overview
  • 20.2. Strengths
  • 20.3. Weaknesses
  • 20.4. Opportunities
  • 20.5. Threats
  • 20.6. Comparison of SWOT Factors

21. CONCLUDING REMARKS

  • 21.1. Chapter Overview

22. SURVEY ANALYSIS

  • 22.1. Chapter Overview
  • 22.2. Distribution by Designation of Respondents
  • 22.3. Distribution by Type of Cell Therapy
  • 22.4. Distribution by Scale of Operation
  • 22.5. Distribution by Source of Cells
  • 22.6. Distribution by Type of Cell Culture System Used
  • 22.7. Distribution by Availability of Fill / Finish Services

23. INTERVIEW TRANSCRIPTS

  • 23.1. Chapter Overview
  • 23.2. Glycostem Therapeutics
    • 23.2.1. Company Overview
    • 23.2.2. Interview Transcript: Troels Jordansen, Chief Executive Officer
  • 23.3. Bio Elpida
    • 23.3.1. Company Overview
    • 23.3.2. Interview Transcript: Gilles Devillers, President
  • 23.4. Gracell Biotechnologies
    • 23.4.1. Company Overview
    • 23.4.2. Interview Transcript: Wei (William) Cao, Chief Executive Officer
  • 23.5. Kadimastem
    • 23.5.1. Company Overview
    • 23.5.2. Interview Transcript: Arik Hasson, Executive VP Research and Development
  • 23.6. RoslinCT
    • 23.6.1. Company Overview
    • 23.6.2. Interview Transcript: Fiona Bellot, Business Development Manager
  • 23.7. University of Minnesota
    • 23.7.1. Company Overview
    • 23.7.2. Interview Transcript: David Mckenna, Professor and American Red Cross Chair in Transfusion Medicine
  • 23.8. Lion TCR
    • 23.8.1. Company Overview
    • 23.8.2. Interview Transcript: Victor Lietao Li, Co-Founder and Chief Executive Officer
  • 23.9. Center for Commercialization of Cancer Immunotherapy / C3i
    • 23.9.1. Company Overview
    • 23.9.2. Interview Transcript: Arnaud Deladeriere, Manager, Business Development & Operations-cGMP Manufacturing Unit
  • 23.10. Waisman Biomanufacturing
    • 23.10.1. Company Overview
    • 23.10.2. Interview Transcript: Brian Dattilo, Manager of Business Development
  • 23.11. Yposkesi
    • 23.11.1. Company Overview
    • 23.11.2. Interview Transcript: Mathilde Girard, Department Leader, Cell Therapy Innovation and Development
  • 23.12. Cell Therapies
    • 23.12.1. Company Overview
    • 23.12.2. Interview Transcript: Tim Oldham, Chief Executive Officer
  • 23.13. CiMaas
    • 23.13.1. Organization Overview
    • 23.13.2. Interview Transcript: Gerard MJ Bos, Chief Executive Officer

24. APPENDIX 1: TABULATED DATA

25. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

  • Figure 3.1 Classification of Advanced Therapy Medicinal Products
  • Figure 3.2 Decentralized Manufacturing: Process Model
  • Figure 3.3 Cell Therapy Manufacturing: Types of Manufacturers
  • Figure 3.4 Cell Therapies: Challenges and Drivers
  • Figure 3.5 Cell Therapies: Potency as a Critical Quality Attribute
  • Figure 3.6 Cell Therapy Manufacturing: Supply Chain Model
  • Figure 4.1 Cell Therapy Manufacturing (Industry Players): Distribution by Company Size
  • Figure 4.2 Cell Therapy Manufacturing (Industry Players): Distribution by Year of Establishment
  • Figure 4.3 Cell Therapy Manufacturing (Industry Players): Distribution by Location of Headquarters (Region-wise)
  • Figure 4.4 Cell Therapy Manufacturing (Industry Players): Distribution by Location of Headquarters (Country-wise)
  • Figure 4.5 Cell Therapy Manufacturing (Industry Players): Distribution by Location of Manufacturing Facilities (Region-wise)
  • Figure 4.6 Cell Therapy Manufacturing (Industry Players): Distribution by Location of Manufacturing Facilities (Country-wise)
  • Figure 4.7 Cell Therapy Manufacturing (Industry Players): Distribution by Type of Manufacturer
  • Figure 4.8 Cell Therapy Manufacturing (Industry Players): Distribution by Type of Cell Manufactured
  • Figure 4.9 Cell Therapy Manufacturing (Industry Players): Distribution by Type of Immune Cell Manufactured
  • Figure 4.10 Cell Therapy Manufacturing (Industry Players): Distribution by Type of Stem Cell Manufactured
  • Figure 4.11 Cell Therapy Manufacturing (Industry Players): Distribution by Source of Cells
  • Figure 4.12 Cell Therapy Manufacturing (Industry Players): Distribution by Scale of Operation
  • Figure 4.13 Cell Therapy Manufacturing (Industry Players): Distribution by Manufacturing Capabilities / Services Offered
  • Figure 4.14 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Location of Headquarters (Region-wise)
  • Figure 4.15 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Location of Headquarters (Country-wise)
  • Figure 4.16 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Location of Manufacturing Facility (Region-wise)
  • Figure 4.17 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Location of Manufacturing Facility (Country-wise)
  • Figure 4.18 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Type of Manufacturer
  • Figure 4.19 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Type of Cell Manufactured
  • Figure 4.20 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Type of Immune Cell Manufactured
  • Figure 4.21 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Type of Stem Cell Manufactured
  • Figure 4.22 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Source of Cells
  • Figure 4.23 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Scale of Operation
  • Figure 4.24 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Manufacturing Capabilities / Services Offered
  • Figure 5.1 Cell Therapy Manufacturing (Industry Players): Distribution by Regulatory Authorities
  • Figure 5.2 Cell Therapy Manufacturing (Non-Industry Players): Distribution of Manufacturing Facilities by Regulatory Authorities
  • Figure 7.1 Key Considerations while Automating Cell Therapy Manufacturing Process
  • Figure 7.2 Requirements for Implementing Closed Systems in Cell Therapy Manufacturing Processes
  • Figure 7.3 Functions of Automated and Closed Systems at Each Step of the Cell Therapy Manufacturing Process
  • Figure 7.4 Advantages and Disadvantages Associated with Single-Use Systems
  • Figure 7.5 Growth Drivers and Roadblocks Related to the Adoption of Automated and Closed Systems
  • Figure 7.6 Cell Therapy Manufacturing: Roadmap for Developing an Automated Device
  • Figure 7.7 Cell Therapy Manufacturing: Comparison of Manual and Automated Processes
  • Figure 7.8 Cell Therapy Manufacturing: Comparison of Manual and Automated Processes Based on Affiliated Costs
  • Figure 7.9 Cell Therapy Manufacturing: Comparison of Manual and Automated Processes Based on Annual Cost of Manufacturing per Batch
  • Figure 8.1 Cognate BioServices: Service Portfolio
  • Figure 8.2 KBI Biopharma: Service Portfolio
  • Figure 8.3 Waisman Biomanufacturing: Service Portfolio
  • Figure 8.4 Waisman Biomanufacturing: Clinical Products Portfolio
  • Figure 8.5 Waisman Biomanufacturing: Quality Assurance and Control
  • Figure 8.6 Waisman Biomanufacturing: Manufacturing Suites
  • Figure 8.7 Waisman Biomanufacturing: Overview of Suite Services
  • Figure 8.8 BioNTech Innovative Manufacturing Services: Service Portfolio
  • Figure 8.9 Cell and Gene Therapy Catapult: Services
  • Figure 8.10 Lonza: Historical Timeline
  • Figure 8.11 Lonza: Key Business Divisions
  • Figure 8.12 Lonza Pharma and Biotech: Service Portfolio
  • Figure 8.13 Lonza: Biological Manufacturing Services
  • Figure 8.14 Lonza: Cell-based Products
  • Figure 8.15 Roslin Cell Therapies: Service Portfolio
  • Figure 8.16 Cell Therapies: Service Portfolio
  • Figure 8.17 FUJIFILM Cellular Dynamics: Service Portfolio
  • Figure 8.18 Minaris Regenerative Medicine: Service Portfolio
  • Figure 8.19 MEDINET: Service Portfolio
  • Figure 8.20 Nikon CeLL Innovation: Service Portfolio
  • Figure 8.21 WuXi AppTec: Service Portfolio
  • Figure 9.1 Center for Cell and Gene Therapy: Operating Segments
  • Figure 9.2 Center for Cell and Gene Therapy: Service Portfolio
  • Figure 9.3 Center for Cell Manufacturing Ireland: Service Portfolio
  • Figure 9.4 Molecular and Cellular Therapeutics: Service Portfolio
  • Figure 9.5 Newcastle Advanced Therapies: Service Portfolio
  • Figure 11.1 Partnerships: Cumulative Year-wise Trend, 2016-2021 (Till February)
  • Figure 11.2 Partnerships: Distribution by Type of Partnership
  • Figure 11.3 Partnerships: Distribution by Year and Type of Partnership
  • Figure 11.4 Partnerships: Distribution by Type of Cell
  • Figure 11.5 Heat Map: Distribution by Year and Type of Cell
  • Figure 11.6 Partnerships: Distribution by Type of Stem Cell
  • Figure 11.7 Partnerships: Distribution by Type of T-Cell
  • Figure 11.8 Partnerships: Distribution by Scale of Operation
  • Figure 11.9 Partnerships: Distribution by Type of Cell and Scale of Operation
  • Figure 11.10 Partnerships: Country-wise Distribution
  • Figure 11.11 Partnerships: Continent-wise Distribution
  • Figure 11.12 Most Active Players: Distribution by Number of Partnerships
  • Figure 11.13 Acquisitions: Cumulative Year-wise Trend, 2016-2021 (Till February)
  • Figure 11.14 Acquisitions: Year-wise Distribution by Type of Cell
  • Figure 11.15 Acquisitions: Country-wise Distribution
  • Figure 11.16 Acquisitions: Continent-wise Distribution
  • Figure 11.17 Acquisitions: Ownership Change Matrix
  • Figure 12.1 Expansions: Cumulative Year-wise Trend, 2016-2021 (Till February)
  • Figure 12.2 Expansions: Distribution by Purpose of Expansion
  • Figure 12.3 Expansions: Distribution by Type of Cell
  • Figure 12.4 Expansions: Distribution by Purpose of Expansion and Type of Cell
  • Figure 12.5 Expansions: Distribution by Scale of Operation
  • Figure 12.6 Expansions: Distribution by Location of Manufacturing Facility (Region-wise)
  • Figure 12.7 Expansions: Distribution by Location of Manufacturing Facility (Country-wise)
  • Figure 12.8 Expansions: Distribution by Purpose of Expansion and Region
  • Figure 12.9 Most Active Players: Distribution by Number of Expansions
  • Figure 12.10 Most Active Players: Distribution by Area of Expansion
  • Figure 12.11 Expansions: Distribution by Region and Area of Expansion
  • Figure 13.1 Big Pharma Players: Distribution by Number of Cell Therapy Manufacturing Focused Initiatives
  • Figure 13.2 Big Pharma Players: Cumulative Distribution by Year of Initiative
  • Figure 13.3 Big Pharma Players: Distribution by Purpose of Initiative
  • Figure 13.4 Big Pharma Players: Distribution by Type of Initiative
  • Figure 13.5 Big Pharma Players: Distribution by Type of Partnership
  • Figure 13.6 Big Pharma Players: Distribution by Type of Expansion
  • Figure 13.7 Big Pharma Players: Distribution by Scale of Operation
  • Figure 13.8 Big Pharma Players: Distribution by Types of Cells
  • Figure 13.9 Big Pharma Players: Distribution by Year of Initiative and Company
  • Figure 13.10 Big Pharma Players: Distribution by Purpose of Initiative and Company
  • Figure 13.11 Big Pharma Players: Distribution by Year and Type of Initiative
  • Figure 13.12 Big Pharma Players: Distribution by Region of Expansion and Company
  • Figure 13.13 Big Pharma Players: Distribution by Type of Cell and Company
  • Figure 13.14 Harvey Ball Analysis: Big Pharma Investment Summary
  • Figure 14.1 Installed Global Capacity for Cell Therapy Manufacturing, in Terms of Number of Cleanrooms (Industry Players): Distribution by Range of Installed Capacity
  • Figure 14.2 Installed Global Capacity for Cell Therapy Manufacturing, in Terms of Number of Cleanrooms (Industry Players): Distribution by Company Size
  • Figure 14.3 Installed Global Capacity for Cell Therapy Manufacturing, in Terms of Number of Cleanrooms (Industry Players): Distribution by Scale of Operation
  • Figure 14.4 Installed Global Capacity for Cell Therapy Manufacturing, in Terms of Number of Cleanrooms (Industry Players): Distribution by Location of Manufacturing Facility
  • Figure 14.5 Installed Global Capacity for Cell Therapy Manufacturing, in Terms of Number of Cleanrooms (Industry Players): Distribution by Company Size and Location of Manufacturing Facility
  • Figure 14.6 Installed Global Capacity for Cell Therapy Manufacturing, in Terms of Number of Cleanrooms (Industry Players): Distribution by Scale of Operation and Location of Manufacturing Facility
  • Figure 14.7 Installed Global Capacity for Cell Therapy Manufacturing, in Terms of Cleanroom Area (Industry Players): Distribution by Range of Installed Capacity
  • Figure 14.8 Installed Global Capacity for Cell Therapy Manufacturing, in Terms of Cleanroom Area (Industry Players): Distribution by Company Size
  • Figure 14.9 Installed Global Capacity for Cell Therapy Manufacturing, in Terms of Cleanroom Area (Industry Players): Distribution by Scale of Operation
  • Figure 14.10 Installed Global Capacity for Cell Therapy Manufacturing, in Terms of Cleanroom Area (Industry Players): Distribution by Location of Manufacturing Facility
  • Figure 14.11 Installed Global Capacity for Cell Therapy Manufacturing, in Terms of Cleanroom Area (Industry Players): Distribution by Company Size and Location of Manufacturing Facility
  • Figure 14.12 Installed Global Capacity for Cell Therapy Manufacturing, in Terms of Cleanroom Area (Industry Players): Distribution by Scale of Operation and Location of Manufacturing Facility
  • Figure 14.13 Installed Global Capacity for Cell Therapy Manufacturing, in Terms of Number of Cleanrooms (Non-Industry Players): Distribution by Range of Installed Capacity
  • Figure 14.14 Installed Global Capacity for Cell Therapy Manufacturing, in Terms of Number of Cleanrooms (Non-Industry Players): Distribution by Scale of Operation
  • Figure 14.15 Installed Global Capacity for Cell Therapy Manufacturing, in Terms of Number of Cleanrooms (Non-Industry Players): Distribution by Location of Manufacturing Facility
  • Figure 14.16 Installed Global Capacity for Cell Therapy Manufacturing, in Terms of Cleanroom Area (Non-Industry Players): Distribution by Range of Installed Capacity
  • Figure 14.17 Installed Global Capacity for Cell Therapy Manufacturing, in Terms of Cleanroom Area (Non-Industry Players): Distribution by Scale of Operation
  • Figure 14.18 Installed Global Capacity for Cell Therapy Manufacturing, in Terms of Cleanroom Area (Non-Industry Players): Distribution by Location of Manufacturing Facility
  • Figure 15.1 Global Demand for Cell Therapies, 2021-2030 (Number of Patients)
  • Figure 15.2 Global Demand for Cell Therapies, 2021-2030 (Billion Cells)
  • Figure 15.3 Global Clinical Demand for Cell Therapies, 2021-2030 (Number of Patients)
  • Figure 15.4 Global Clinical Demand for Cell Therapies, 2021-2030: Distribution by Type of Cell Therapy (Number of Patients)
  • Figure 15.5 Global Clinical Demand for Cell Therapies, 2021-2030: Distribution by Geographical Location (Number of Patients)
  • Figure 15.6 Global Commercial Demand for Cell Therapies, 2021-2030 (Number of Patients)
  • Figure 15.7 Global Commercial Demand for Cell Therapies, 2021-2030: Distribution by Type of Cell Therapy (Number of Patients)
  • Figure 15.8 Global Commercial Demand for Cell Therapies, 2021-2030: Distribution by Geographical Location (Number of Patients)
  • Figure 16.1 Targeted Therapies: Pricing Model Based on Patient Segment
  • Figure 17.1 Make versus Buy Decision Making Framework
  • Figure 17.2 Make versus Buy Decision Making: Possible Scenario Descriptions
  • Figure 18.1 Global Cell Therapy Manufacturing Market, 2021-2030 (USD Million)
  • Figure 18.2 Cell Therapy Manufacturing Market: Distribution by Type of Cell Therapy, 2021-2030 (USD Million)
  • Figure 18.3 Cell Therapy Manufacturing Market: Distribution by Source of Cells, 2021-2030 (USD Million)
  • Figure 18.4 Cell Therapy Manufacturing Market: Distribution by Scale of Operation, 2021-2030 (USD Million)
  • Figure 18.5 Cell Therapy Manufacturing Market: Distribution by Purpose of Manufacturing, 2021-2030 (USD Million)
  • Figure 18.6 Cell Therapy Manufacturing Market: Distribution by Region, 2021-2030 (USD Million)
  • Figure 18.7 Global Commercial Scale Manufacturing Market for T-cell Therapies, 2021-2030 (USD Million)
  • Figure 18.8 Commercial Scale Manufacturing Market for T-cell Therapies: Distribution by Type of Therapy, 2021-2030 (USD Million)
  • Figure 18.9 Commercial Scale Manufacturing Market for T-cell Therapies: Distribution by Source of Cells, 2021-2030 (USD Million)
  • Figure 18.10 Commercial Scale Manufacturing Market for T-cell Therapies: Distribution by Region, 2021-2030 (USD Million)
  • Figure 18.11 Global Commercial Scale Manufacturing Market for NK Cell Therapies, 2021-2030 (USD Million)
  • Figure 18.12 Commercial Scale Manufacturing Market for NK Cell Therapies: Distribution by Source of Cells, 2021-2030 (USD Million)
  • Figure 18.13 Commercial Scale Manufacturing Market for NK Cell Therapies: Distribution by Region, 2021-2030 (USD Million)
  • Figure 18.14 Global Commercial Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies, 2021-2030 (USD Million)
  • Figure 18.15 Commercial Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies: Distribution by Type of Therapy, 2021-2030 (USD Million)
  • Figure 18.16 Commercial Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies: Distribution by Region, 2021-2030 (USD Million)
  • Figure 18.17 Global Commercial Scale Manufacturing Market for Stem Cell Therapies, 2021-2030 (USD Million)
  • Figure 18.18 Commercial Scale Manufacturing Market for Stem Cell Therapies: Distribution by Source of Cells, 2021-2030 (USD Million)
  • Figure 18.19 Commercial Scale Manufacturing Market for Stem Cell Therapies: Distribution by Region, 2021-2030 (USD Million)
  • Figure 18.20 Global Clinical Scale Manufacturing Market for T-cell Therapies, 2021-2030 (USD Million)
  • Figure 18.21 Clinical Scale Manufacturing Market for T-cell Therapies: Distribution by Type of Therapy, 2021-2030 (USD Million)
  • Figure 18.22 Clinical Scale Manufacturing Market for T-cell Therapies: Distribution by Source of Cells, 2021-2030 (USD Million)
  • Figure 18.23 Clinical Scale Manufacturing Market for T-cell Therapies: Distribution by Region, 2021-2030 (USD Million)
  • Figure 18.24 Global Clinical Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies, 2021-2030 (USD Million)
  • Figure 18.25 Clinical Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies: Distribution by Type of Therapy, 2021-2030 (USD Million)
  • Figure 18.26 Clinical Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies: Distribution by Source of Cells, 2021-2030 (USD Million)
  • Figure 18.27 Clinical Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies: Distribution by Region, 2021-2030 (USD Million)
  • Figure 18.28 Global Clinical Scale Manufacturing Market for NK Cell Therapies, 2021-2030 (USD Million)
  • Figure 18.29 Clinical Scale Manufacturing Market for NK Cell Therapies: Distribution by Source of Cells, 2021-2030 (USD Million)
  • Figure 18.30 Clinical Scale Manufacturing Market for NK Cell Therapies: Distribution by Region, 2021-2030 (USD Million)
  • Figure 18.31 Global Clinical Scale Manufacturing Market for Stem Cell Therapies, 2021-2030 (USD Million)
  • Figure 18.32 Clinical Scale Manufacturing Market for Stem Cell Therapies: Distribution by Source of Cells, 2021-2030 (USD Million)
  • Figure 18.33 Clinical Scale Manufacturing Market for Stem Cell Therapies: Distribution by Region, 2021-2030 (USD Million)
  • Figure 19.1 Cell Therapy Manufacturing: Grid Analysis by Purpose of Production, Scale of Operation and Types of Cells
  • Figure 19.2 Cell Therapy Manufacturing: Logo Landscape, Immune Cells
  • Figure 19.3 Cell Therapy Manufacturing: Logo Landscape, Stem Cells
  • Figure 19.4 Cell Therapy Manufacturing (Industry Players): Distribution by Location of Manufacturing Facility
  • Figure 19.5 Cell Therapy Manufacturers (Non-Industry Players): Distribution by Location of Manufacturing Facility
  • Figure 20.1 Cell Therapy Manufacturing: SWOT Analysis
  • Figure 20.2 Comparison of SWOT Factors: Harvey Ball Analysis
  • Figure 21.1 Concluding Remarks: Summary of the Current Market Landscape (Industry Players)
  • Figure 21.2 Concluding Remarks: Summary of the Current Market Landscape (Non-Industry Players)
  • Figure 21.3 Concluding Remarks: Summary of Partnerships
  • Figure 21.4 Concluding Remarks: Summary of Facility Expansions
  • Figure 21.5 Concluding Remarks: Summary of Big Pharma Initiatives
  • Figure 21.6 Concluding Remarks: Summary of Capacity Analysis
  • Figure 21.7 Concluding Remarks: Summary of Demand Analysis
  • Figure 21.8 Concluding Remarks: Market Sizing and Opportunity Analysis
  • Figure 22.1 Survey Insights: Distribution of Respondents by Type of Organization
  • Figure 22.2 Survey Insights: Distribution of Respondents by Location of Manufacturing Facility
  • Figure 22.3 Survey Insights: Distribution of Respondents by Designation and Seniority
  • Figure 22.4 Survey Insights: Distribution by Type of Cell Therapy
  • Figure 22.5 Survey Insights: Distribution by Scale of Operation
  • Figure 22.6 Survey Insights: Distribution by Source of Cells
  • Figure 22.7 Survey Insights: Distribution by Type of Cell Culture System Used
  • Figure 22.8 Survey Insights: Distribution by Availability of Fill / Finish Services

List Of Tables

  • Table 3.1 Applications of Cell-based Therapies
  • Table 3.2 Key Differences between Cell Therapy and Biotechnology Products
  • Table 3.3 Cell-based Therapies: Commercialized Products
  • Table 3.4 Assessment of Key Cell Therapy Manufacturing Steps
  • Table 3.5 Advantages and Disadvantages Associated with Centralized and Decentralized Manufacturing Models
  • Table 4.1 Cell Therapy Manufacturing: List of Industry Players
  • Table 4.2 Cell Therapy Manufacturing (Industry Players): Information on Type of Manufacturer
  • Table 4.3 Cell Therapy Manufacturing (Industry Players): Information on Type of Cell Manufactured
  • Table 4.4 Cell Therapy Manufacturing (Industry Players): Information on Source of Cells and Type of Cell Culture System Used
  • Table 4.5 Cell Therapy Manufacturing (Industry Players): Information on Scale of Operation
  • Table 4.6 Cell Therapy Manufacturing (Industry Players): Information on Manufacturing Capabilities / Services Offered
  • Table 4.7 Cell Therapy Manufacturing: List of Non-Industry Players
  • Table 4.8 Cell Therapy Manufacturing (Non-Industry Players): Information on Type of Manufacturer
  • Table 4.9 Cell Therapy Manufacturing (Non-Industry Players): Information on Type of Cell Manufactured
  • Table 4.10 Cell Therapy Manufacturing (Non-Industry Players): Information on Source of Cells and Type of Cell Culture System Used
  • Table 4.11 Cell Therapy Manufacturing (Non-Industry Players): Information on Scale of Operation
  • Table 4.12 Cell Therapy Manufacturing (Non-Industry Players): Information on Manufacturing Capabilities / Services Offered
  • Table 5.1 Cell Therapy Manufacturing (Industry Players): Regulatory Authorities
  • Table 5.2 Cell Therapy Manufacturing (Non-Industry Players): Regulatory Authorities
  • Table 5.3 Cell Therapy: Regulatory Considerations
  • Table 6.1 Cell Therapy Manufacturing: Roadmap for the US
  • Table 6.2 Cell Processing: Challenges and Strategies
  • Table 6.3 Cell Preservation, Distribution and Handling: Challenges and Strategies
  • Table 6.4 Process Monitoring and Quality Control: Challenges and Strategies
  • Table 6.5 Standardization and Regulatory Support: Challenges and Strategies
  • Table 6.6 Workforce Development: Challenges and Strategies
  • Table 6.7 Supply Chain and Logistics: Challenges and Strategies
  • Table 6.8 Cell Therapy Manufacturing: Roadmap for the Asia Pacific Economic Cooperation (APEC)
  • Table 7.1 Cell Therapy Manufacturing: List of Automated and Closed Cell Therapy Processing Systems
  • Table 7.2 Cell Therapy Manufacturing: Observed Changes in Scale-up Scenario while Switching from Manual to Automated Operations
  • Table 8.1 Cognate BioServices: Company Overview
  • Table 8.2 Cognate BioServices: Overview of Manufacturing Capabilities
  • Table 8.3 Cognate BioServices: Partnerships
  • Table 8.4 Cognate BioServices: Future Outlook
  • Table 8.5 KBI Biopharma: Company Overview
  • Table 8.6 KBI Biopharma: Overview of Manufacturing Capabilities
  • Table 8.7 KBI Biopharma: Partnerships
  • Table 8.8 KBI Biopharma: Future Outlook
  • Table 8.9 Waisman Biomanufacturing: Company Overview
  • Table 8.10 Waisman Biomanufacturing: Overview of Manufacturing Capabilities
  • Table 8.11 Waisman Biomanufacturing: Partnerships
  • Table 8.12 Waisman Biomanufacturing: Future Outlook
  • Table 8.13 BioNTech Innovative Manufacturing Services: Company Overview
  • Table 8.14 BioNTech Innovative Manufacturing Services: Overview of Manufacturing Capabilities
  • Table 8.15 BioNTech Innovative Manufacturing Services: Partnerships
  • Table 8.16 BioNTech Innovative Manufacturing Services: Future Outlook
  • Table 8.17 Cell and Gene Therapy Catapult: Company Overview
  • Table 8.18 Cell and Gene Therapy Catapult: Overview of Manufacturing Capabilities
  • Table 8.19 Cell and Gene Therapy Catapult: Partnerships
  • Table 8.20 Cell and Gene Therapy Catapult: Future Outlook
  • Table 8.21 Lonza: Company Overview
  • Table 8.22 Lonza: Global Manufacturing Sites
  • Table 8.23 Lonza: Overview of Manufacturing Capabilities
  • Table 8.24 Lonza: Partnerships
  • Table 8.25 Lonza: Future Outlook
  • Table 8.26 Roslin Cell Therapies: Company Overview
  • Table 8.27 Roslin Cell Therapies: Overview of Manufacturing Capabilities
  • Table 8.28 Roslin Cell Therapies: Partnerships
  • Table 8.29 Roslin Cell Therapies: Future Outlook
  • Table 8.30 Cell Therapies: Company Overview
  • Table 8.31 Cell Therapies: Overview of Manufacturing Capabilities
  • Table 8.32 Cell Therapies: Partnerships
  • Table 8.33 Cell Therapies: Future Outlook
  • Table 8.34 FUJIFILM Cellular Dynamics: Company Overview
  • Table 8.35 FUJIFILM Cellular Dynamics: Overview of Manufacturing Capabilities
  • Table 8.36 FUJIFILM Cellular Dynamics: Partnerships
  • Table 8.37 FUJIFILM Cellular Dynamics: Future Outlook
  • Table 8.38 Minaris Regenerative Medicine: Company Overview
  • Table 8.39 Minaris Regenerative Medicine: Overview of Manufacturing Capabilities
  • Table 8.40 Minaris Regenerative Medicine: Partnerships
  • Table 8.41 Minaris Regenerative Medicine: Future Outlook
  • Table 8.42 MEDINET: Company Overview
  • Table 8.43 MEDINET: Overview of Manufacturing Capabilities
  • Table 8.44 MEDINET: Partnerships
  • Table 8.45 Nikon CeLL Innovation: Company Overview
  • Table 8.46 Nikon CeLL Innovation: Overview of Manufacturing Capabilities
  • Table 8.47 Nikon CeLL Innovation: Partnerships
  • Table 8.48 Nikon CeLL Innovation: Future Outlook
  • Table 8.49 WuXi AppTec: Company Overview
  • Table 8.50 WuXi AppTec: Overview of Manufacturing Capabilities
  • Table 8.51 WuXi AppTec: Partnerships
  • Table 8.52 WuXi AppTec: Future Outlook
  • Table 9.1 Center for Cell and Gene Therapy: Overview of Manufacturing Facilities and Capabilities
  • Table 9.2 Center for Cell Manufacturing Ireland: Overview of Manufacturing Facilities and Capabilities
  • Table 9.3 Clinical Cell and Vaccine Production Facility: Overview of Manufacturing Facilities and Capabilities
  • Table 9.4 Guy's and St. Thomas GMP Facility: Overview of Manufacturing Facilities and Capabilities
  • Table 9.5 Laboratory for Cell and Gene Medicine: Overview of Manufacturing Facilities and Capabilities
  • Table 9.6 Molecular and Cellular Therapeutics: Overview of Manufacturing Facilities and Capabilities
  • Table 9.7 Newcastle Advanced Therapies: Overview of Manufacturing Facilities and Capabilities
  • Table 9.8 Rayne Cell Therapy Suite: Overview of Manufacturing Facilities and Capabilities
  • Table 9.9 Scottish National Blood Transfusion Services: Overview of Manufacturing Services and Capabilities
  • Table 9.10 Sydney Cell and Gene Therapy: Overview of Manufacturing Facilities and Capabilities
  • Table 10.1 Cell Therapy Manufacturing: List of Non-Profit Organizations
  • Table 10.2 CellCAN: Overview
  • Table 10.3 Cell Therapy Manufacturing Cooperative Research Center: Overview
  • Table 10.4 National Cell Manufacturing Consortium: Overview
  • Table 10.5 California's Institute of Regenerative Medicine: Overview
  • Table 11.1 Cell Therapy Manufacturing: List of Partnerships
  • Table 11.2 Partnerships: Information on Types of Cells
  • Table 11.3 Partnerships: Information on Subtypes of Cells
  • Table 11.4 Partnerships: Information on Scales of Manufacturing
  • Table 11.5 Cell Therapy Manufacturing: List of Acquisitions
  • Table 12.1 Cell Therapy Manufacturing: List of Expansions
  • Table 12.2 Expansions: Information on Type of Cell
  • Table 12.3 Expansions: Information on Scale of Operation
  • Table 13.1 Big Pharma Players: List of Cell Therapy Manufacturing Initiatives
  • Table 14.1 Installed Global Capacity for Cell Therapy Manufacturing, in Terms of Number of Cleanrooms: Average Capacity by Company Size (Sample Data Set for Industry Players)
  • Table 14.2 Installed Global Capacity for Cell Therapy Manufacturing, in Terms of Cleanroom Area: Average Capacity by Company Size (Sample Data Set for Industry Players)
  • Table 14.3 Installed Global Capacity for Cell Therapy Manufacturing, in Terms of Number of Cleanrooms (Industry Players): Distribution by Company Size
  • Table 14.4 Installed Global Capacity for Cell Therapy Manufacturing, in Terms of Cleanroom Area (Industry Players): Distribution by Company Size
  • Table 14.5 Installed Global Capacity for Cell Therapy Manufacturing, in Terms of Number of Cleanrooms: Average Capacity for Non-Industry Players
  • Table 14.6 Installed Global Capacity for Cell Therapy Manufacturing, in Terms of Cleanroom Area: Average Capacity for Non-Industry Players
  • Table 16.1 Costs Associated with the Manufacturing of Stem Cell Therapies
  • Table 16.2 Price of Marketed Gene / Cell Therapies
  • Table 16.3 Price of Marketed Target Drugs
  • Table 16.4 T-cell Immunotherapies: Expert Opinions on Pricing
  • Table 16.5 CAR-T Cell Therapies: Reimbursement Landscape
  • Table 18.1 Active Clinical Studies for Autologous Cell Therapies
  • Table 18.2 Active Clinical Studies for Allogeneic Cell Therapies
  • Table 18.3 Active Clinical Studies for Autologous Cell Therapies: Distribution by Patients Enrolled
  • Table 18.4 Active Clinical Studies for Allogeneic Cell Therapies: Distribution by Patients Enrolled
  • Table 22.1 Survey Insights: Overview of Respondents
  • Table 22.2 Survey Insights: Designations and Seniority Levels
  • Table 22.3 Survey Insights: Type of Cell Therapy
  • Table 22.4 Survey Insights: Scale of Operation
  • Table 22.5 Survey Insights: Source of Cells
  • Table 22.6 Survey Insights: Type of Cell Culture System Used
  • Table 22.7 Survey Insights: Availability of Fill / Finish Services
  • Table 23.1 Glycostem Therapeutics: Company Snapshot
  • Table 23.2 Bio Elpida: Company Snapshot
  • Table 23.3 Gracell Biotechnologies: Company Snapshot
  • Table 23.4 Kadimastem: Company Snapshot
  • Table 23.5 RoslinCT: Company Snapshot
  • Table 23.6 University of Minnesota: Organization Snapshot
  • Table 23.7 Lion TCR: Company Snapshot
  • Table 23.8 Center for Commercialization of Cancer Immunotherapy / C3i: Company Snapshot
  • Table 23.9 Waisman Biomanufacturing: Company Snapshot
  • Table 23.10 Yposkesi: Company Snapshot
  • Table 23.11 Cell Therapies: Company Snapshot
  • Table 23.12 CiMaas: Company Snapshot
  • Table 24.1 Cell Therapy Manufacturing (Industry Players): Distribution by Company Size
  • Table 24.2 Cell Therapy Manufacturing (Industry Players): Distribution by Year of Establishment
  • Table 24.3 Cell Therapy Manufacturing (Industry Players): Distribution by Location of Headquarters (Region-wise)
  • Table 24.4 Cell Therapy Manufacturing (Industry Players): Distribution by Location of Headquarters (Country-wise)
  • Table 24.5 Cell Therapy Manufacturing (Industry Players): Distribution by Location of Manufacturing Facilities (Region-wise)
  • Table 24.6 Cell Therapy Manufacturing (Industry Players): Distribution by Location of Manufacturing Facilities (Country-wise)
  • Table 24.7 Cell Therapy Manufacturing (Industry Players): Distribution by Type of Manufacturer
  • Table 24.8 Cell Therapy Manufacturing (Industry Players): Distribution by Type of Cell Manufactured
  • Table 24.9 Cell Therapy Manufacturing (Industry Players): Distribution by Type of Immune Cell Manufactured
  • Table 24.10 Cell Therapy Manufacturing (Industry Players): Distribution by Type of Stem Cell Manufactured
  • Table 24.11 Cell Therapy Manufacturing (Industry Players): Distribution by Source of Cells
  • Table 24.12 Cell Therapy Manufacturing (Industry Players): Distribution by Scale of Operation
  • Table 24.13 Cell Therapy Manufacturing (Industry Players): Distribution by Manufacturing Capabilities / Services Offered
  • Table 24.14 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Location of Headquarters (Region-wise)
  • Table 24.15 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Location of Headquarters (Country-wise)
  • Table 24.16 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Location of Manufacturing Facility (Region-wise)
  • Table 24.17 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Location of Manufacturing Facility (Country-wise)
  • Table 24.18 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Type of Manufacturer
  • Table 24.19 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Type of Cell Manufactured
  • Table 24.20 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Type of Immune Cell Manufactured
  • Table 24.21 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Type of Stem Cell Manufactured
  • Table 24.22 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Source of Cells
  • Table 24.23 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Scale of Operation
  • Table 24.24 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Manufacturing Capabilities / Services Offered
  • Table 24.25 Cell Therapy Manufacturing (Industry Players): Distribution of Manufacturing Facilities by Regulatory Authorities
  • Table 24.26 Cell Therapy Manufacturing (Non-Industry Players): Distribution of Manufacturing Facilities by Regulatory Authorities
  • Table 24.27 Partnerships: Cumulative Year-wise Trend, 2016-2021 (Till February)
  • Table 24.28 Partnerships: Distribution by Type of Partnership
  • Table 24.29 Partnerships: Distribution by Year and Type of Partnership
  • Table 24.30 Partnerships: Distribution by Type of Cell
  • Table 24.31 Partnerships: Distribution by Type of Stem Cell
  • Table 24.32 Partnerships: Distribution by Type of T-Cell
  • Table 24.33 Partnerships: Distribution by Scale of Operation
  • Table 24.34 Partnerships: Distribution by Type of Cell and Scale of Operation
  • Table 24.35 Partnerships: Country-wise Distribution
  • Table 24.36 Partnerships: Continent-wise Distribution
  • Table 24.37 Most Active Players: Distribution by Number of Partnerships
  • Table 24.38 Acquisitions: Cumulative Year-wise Trend, 2016-2021 (Till February)
  • Table 24.39 Acquisitions: Year-wise Distribution by Type of Cell
  • Table 24.40 Acquisitions: Country-wise Distribution
  • Table 24.41 Acquisitions: Continent-wise Distribution
  • Table 24.42 Acquisitions: Ownership Change Matrix
  • Table 24.43 Expansions: Cumulative Year-wise Trend, 2016-2021 (Till February)
  • Table 24.44 Expansions: Distribution by Purpose of Expansion
  • Table 24.45 Expansions: Distribution by Type of Cell
  • Table 24.46 Expansions: Distribution by Purpose of Expansion and Type of Cell
  • Table 24.47 Expansions: Distribution by Scale of Operation
  • Table 24.48 Expansions: Distribution by Location of Manufacturing Facility (Region-wise)
  • Table 24.49 Expansions: Distribution by Location of Manufacturing Facility (Country-wise)
  • Table 24.50 Expansions: Distribution by Purpose of Expansion and Region
  • Table 24.51 Most Active Players: Distribution by Number of Expansions
  • Table 24.52 Most Active Players: Distribution by Area of Expansion
  • Table 24.53 Big Pharma Players: Distribution by Number of Cell Therapy Manufacturing Focused Initiatives
  • Table 24.54 Big Pharma Players: Cumulative Distribution by Year of Initiative
  • Table 24.55 Big Pharma Players: Distribution by Purpose of Initiative
  • Table 24.56 Big Pharma Players: Distribution by Type of Initiative
  • Table 24.57 Big Pharma Players: Distribution by Type of Partnership
  • Table 24.58 Big Pharma Players: Distribution by Type of Expansion
  • Table 24.59 Big Pharma Players: Distribution by Scale of Operation
  • Table 24.60 Big Pharma Players: Distribution by Types of Cells
  • Table 24.61 Big Pharma Players: Distribution by Purpose of Initiative and Company
  • Table 24.62 Big Pharma Players: Distribution by Year and Type of Initiative
  • Table 24.63 Big Pharma Players: Distribution by Region of Expansion and Company
  • Table 24.64 Installed Global Capacity for Cell Therapy Manufacturing, in Terms of Number of Cleanrooms (Industry Players): Distribution by Company Size
  • Table 24.65 Installed Global Capacity for Cell Therapy Manufacturing, in Terms of Number of Cleanrooms (Industry Players): Distribution by Scale of Operation
  • Table 24.66 Installed Global Capacity for Cell Therapy Manufacturing, in Terms of Number of Cleanrooms (Industry Players): Distribution by Location of Manufacturing Facility
  • Table 24.67 Installed Global Capacity for Cell Therapy Manufacturing, in Terms of Number of Cleanrooms (Industry Players): Distribution by Company Size and Location of Manufacturing Facility
  • Table 24.68 Installed Global Capacity for Cell Therapy Manufacturing, in Terms of Number of Cleanrooms (Industry Players): Distribution by Scale of Operation and Location of Manufacturing Facility
  • Table 24.69 Installed Global Capacity for Cell Therapy Manufacturing, in Terms of Cleanroom Area (Industry Players): Distribution by Company Size
  • Table 24.70 Installed Global Capacity for Cell Therapy Manufacturing, in Terms of Cleanroom Area (Industry Players): Distribution by Scale of Operation
  • Table 24.71 Installed Global Capacity for Cell Therapy Manufacturing, in Terms of Cleanroom Area (Industry Players): Distribution by Location of Manufacturing Facility
  • Table 24.72 Installed Global Capacity for Cell Therapy Manufacturing, in Terms of Cleanroom Area (Industry Players): Distribution by Company Size and Location of Manufacturing Facility
  • Table 24.73 Installed Global Capacity for Cell Therapy Manufacturing, in Terms of Cleanroom Area (Industry Players): Distribution by Scale of Operation and Location of Manufacturing Facility
  • Table 24.74 Installed Global Capacity for Cell Therapy Manufacturing, in Terms of Number of Cleanrooms (Non-Industry Players): Distribution by Scale of Operation
  • Table 24.75 Installed Global Capacity for Cell Therapy Manufacturing, in Terms of Number of Cleanrooms (Non-Industry Players): Distribution by Location of Manufacturing Facility
  • Table 24.76 Installed Global Capacity for Cell Therapy Manufacturing, in Terms of Cleanroom Area (Non-Industry Players): Distribution by Scale of Operation
  • Table 24.77 Installed Global Capacity for Cell Therapy Manufacturing, in Terms of Cleanroom Area (Non-Industry Players): Distribution by Location of Manufacturing Facility
  • Table 24.78 Global Demand for Cell Therapies, 2021-2030 (Number of Patients)
  • Table 24.79 Global Demand for Cell Therapies, 2021-2030 (Billion Cells)
  • Table 24.80 Global Clinical Demand for Cell Therapies, 2021-2030 (Number of Patients)
  • Table 24.81 Global Clinical Demand for Cell Therapies, 2021-2030: Distribution by Type of Cell Therapy (Number of Patients)
  • Table 24.82 Global Clinical Demand for Cell Therapies, 2021-2030: Distribution by Geographical Location (Number of Patients)
  • Table 24.83 Global Commercial Demand for Cell Therapies, 2021-2030 (Number of Patients)
  • Table 24.84 Global Commercial Demand for Cell Therapies, 2021-2030: Distribution by Type of Cell Therapy (Number of Patients)
  • Table 24.85 Global Commercial Demand for Cell Therapies, 2021-2030: Distribution by Geographical Location (Number of Patients)
  • Table 24.86 Global Cell Therapy Manufacturing Market, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
  • Table 24.87 Cell Therapy Manufacturing Market, Conservative, Base and Optimistic Scenarios: Distribution by Type of Cell Therapy, 2021-2030 (USD Million)
  • Table 24.88 Cell Therapy Manufacturing Market, Conservative, Base and Optimistic Scenarios: Distribution by Source of Cells, 2021-2030 (USD Million)
  • Table 24.89 Cell Therapy Manufacturing Market, Conservative, Base and Optimistic Scenarios: Distribution by Scale of Operation, 2021-2030 (USD Million)
  • Table 24.90 Cell Therapy Manufacturing Market, Conservative, Base and Optimistic Scenarios: Distribution by Purpose of Manufacturing, 2021-2030 (USD Million)
  • Table 24.91 Cell Therapy Manufacturing Market, Conservative, Base and Optimistic Scenarios: Distribution by Region, 2021-2030 (USD Million)
  • Table 24.92 Global Commercial Scale Manufacturing Market for T-cell Therapies, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
  • Table 24.93 Commercial Scale Manufacturing Market for T-cell Therapies, Conservative, Base and Optimistic Scenarios: Distribution by Type of Therapy, 2021-2030 (USD Million)
  • Table 24.94 Commercial Scale Manufacturing Market for T-cell Therapies, Conservative, Base and Optimistic Scenarios: Distribution by Source of Cells, 2021-2030 (USD Million)
  • Table 24.95 Commercial Scale Manufacturing Market for T-cell Therapies, Conservative, Base and Optimistic Scenarios: Distribution by Region, 2021-2030 (USD Million)
  • Table 24.96 Global Commercial Scale Manufacturing Market for NK Cell Therapies, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
  • Table 24.97 Commercial Scale Manufacturing Market for NK Cell Therapies, Conservative, Base and Optimistic Scenarios: Distribution by Source of Cells, 2021-2030 (USD Million)
  • Table 24.98 Commercial Scale Manufacturing Market for NK Cell Therapies, Conservative, Base and Optimistic Scenarios: Distribution by Region, 2021-2030 (USD Million)
  • Table 24.99 Global Commercial Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
  • Table 24.100 Commercial Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies, Conservative, Base and Optimistic Scenarios: Distribution by Type of Therapy, 2021-2030 (USD Million)
  • Table 24.101 Commercial Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies, Conservative, Base and Optimistic Scenarios: Distribution by Region, 2021-2030 (USD Million)
  • Table 24.102 Global Commercial Scale Manufacturing Market for Stem Cell Therapies, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
  • Table 24.103 Commercial Scale Manufacturing Market for Stem Cell Therapies, Conservative, Base and Optimistic Scenarios: Distribution by Source of Cells, 2021-2030 (USD Million)
  • Table 24.104 Commercial Scale Manufacturing Market for Stem Cell Therapies, Conservative, Base and Optimistic Scenarios: Distribution by Region, 2021-2030 (USD Million)
  • Table 24.105 Global Clinical Scale Manufacturing Market for T-cell Therapies, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
  • Table 24.106 Clinical Scale Manufacturing Market for T-cell Therapies, Conservative, Base and Optimistic Scenarios: Distribution by Type of Therapy, 2021-2030 (USD Million)
  • Table 24.107 Clinical Scale Manufacturing Market for T-cell Therapies, Conservative, Base and Optimistic Scenarios: Distribution by Source of Cells, 2021-2030 (USD Million)
  • Table 24.108 Clinical Scale Manufacturing Market for T-cell Therapies, Conservative, Base and Optimistic Scenarios: Distribution by Region, 2021-2030 (USD Million)
  • Table 24.109 Global Clinical Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
  • Table 24.110 Clinical Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies, Conservative, Base and Optimistic Scenarios: Distribution by Type of Therapy, 2021-2030 (USD Million)
  • Table 24.111 Clinical Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies, Conservative, Base and Optimistic Scenarios: Distribution by Source of Cells, 2021-2030 (USD Million)
  • Table 24.112 Clinical Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies, Conservative, Base and Optimistic Scenarios: Distribution by Region, 2021-2030 (USD Million)
  • Table 24.113 Global Clinical Scale Manufacturing Market for NK Cell Therapies, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
  • Table 24.114 Clinical Scale Manufacturing Market for NK Cell Therapies, Conservative, Base and Optimistic Scenarios: Distribution by Source of Cells, 2021-2030 (USD Million)
  • Table 24.115 Clinical Scale Manufacturing Market for NK Cell Therapies, Conservative, Base and Optimistic Scenarios: Distribution by Region, 2021-2030 (USD Million)
  • Table 24.116 Global Clinical Scale Manufacturing Market for Stem Cell Therapies, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
  • Table 24.117 Clinical Scale Manufacturing Market for Stem Cell Therapies, Conservative, Base and Optimistic Scenarios: Distribution by Source of Cells, 2021-2030 (USD Million)
  • Table 24.118 Clinical Scale Manufacturing Market for Stem Cell Therapies, Conservative, Base and Optimistic Scenarios: Distribution by Region, 2021-2030 (USD Million)
  • Table 24.119 Survey Insights: Distribution of Respondents by Type of Organization
  • Table 24.120 Survey Insights: Distribution of Respondents by Location of Manufacturing Facility
  • Table 24.121 Survey Insights: Distribution of Respondents by Designation and Seniority
  • Table 24.122 Survey Insights: Distribution by Type of Cell Therapy
  • Table 24.123 Survey Insights: Distribution by Scale of Operation
  • Table 24.124 Survey Insights: Distribution by Source of Cells
  • Table 24.125 Survey Insights: Distribution by Type of Cell Culture System Used
  • Table 24.126 Survey Insights: Distribution by Availability of Fill / Finish Services

List Of Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report.

  • 1. 3P Biopharmaceuticals
  • 2. 3SBio
  • 3. A2 Biotherapeutics
  • 4. A2 Healthcare
  • 5. Abeona Therapeutics
  • 6. Accellta
  • 7. Achilles Therapeutics
  • 8. Adaptimmune
  • 9. Adva Biotechnology
  • 10. Advanced Cell Therapy Laboratory, Yale School of Medicine
  • 11. Advent Bioservices
  • 12. AGC Biologics
  • 13. Agenus (AgenTus Therapeutics)
  • 14. Akron Biotech
  • 15. Alberta Cell Therapy Manufacturing (ACTM)
  • 16. Allele Biotechnology and Pharmaceuticals
  • 17. Allogene Therapeutics
  • 18. Anterogen
  • 19. apceth Biopharma
  • 20. ArchiMed
  • 21. Aspire Health Science
  • 22. Astellas Pharma
  • 23. Asterias Biotherapeutics
  • 24. Astero Bio (acquired by BioLife Solutions)
  • 25. Asymptote
  • 26. Atara Biotherapeutics
  • 27. Athersys
  • 28. Austrianova
  • 29. Autolus Therapeutics
  • 30. Bay City Capital
  • 31. Bayer
  • 32. Bellicum Pharmaceuticals
  • 33. Bio Elpida
  • 34. BioCardia
  • 35. BioCentriq
  • 36. BioInno Bioscience
  • 37. Bioinova
  • 38. BioNTech IMFS
  • 39. Biopharmaceutical Development Program, National Cancer Institute
  • 40. BioRestorative Therapies
  • 41. BioTherapeutics Unit, Netherlands Cancer Institute
  • 42. bluebird bio
  • 43. BlueRock Therapeutics (acquired by Bayer)
  • 44. Bone Therapeutics
  • 45. Boyalife
  • 46. BrainStorm Cell Therapeutics
  • 47. Brammer Bio
  • 48. BriaCell Therapeutics
  • 49. Bristol Myers Squibb
  • 50. C3i (Center of Excellence for Cellular Therapy)
  • 51. Caladrius Biosciences
  • 52. CancerRop
  • 53. Capricor Therapeutics
  • 54. CariCord (acquired by Celularity)
  • 55. CARsgen Therapeutics
  • 56. Catalent
  • 57. Catalent Biologics
  • 58. Catapult Therapy TCR (acquired by Cell Medica)
  • 59. Celgene
  • 60. Cell and Gene Therapy Catapult
  • 61. Cell and Gene Therapy Laboratory, Children's Hospital of Philadelphia
  • 62. Cell Medica
  • 63. Cell Therapies
  • 64. Cell Therapies Core, Moffitt Cancer Center
  • 65. Cell Therapy and Regenerative Medicine, University of Utah
  • 66. Cell Therapy Manufacturing Facility, MedStar Georgetown University Hospital
  • 67. Cell Therapy Suite, University of Birmingham
  • 68. Cell-Easy
  • 69. Cellectis
  • 70. Cellex Cell Professionals
  • 71. CELLforCURE
  • 72. Cellin Technologies
  • 73. CellMP (subsidiary of Emmecell)
  • 74. Cells for Sight Stem Cell Therapy Research Unit, University College London
  • 75. Cellular Biomedicine
  • 76. Cellular Therapy Core, Sidney Kimmel Comprehensive Cancer Center
  • 77. Cellular Therapy Core, University of Texas
  • 78. Cellular Therapy Integrated Services (CTIS), Case Western Reserve University
  • 79. Celonic
  • 80. Celularity
  • 81. Celyad
  • 82. Center for Biomedical Engineering and Advanced Manufacturing, McMaster University
  • 83. Center for Cell and Gene Therapy, Baylor College of Medicine
  • 84. Center for International Blood and Marrow Transplant Research
  • 85. Centre for Biological Engineering, Loughborough University
  • 86. Centre for Cell and Gene Tissue Therapeutics, Royal Free Hospital London
  • 87. Centre for Cell and Vector Production (CCVP)
  • 88. Centre for Cell Manufacturing Ireland (CCMI), NUI Galway
  • 89. Centre for Stem Cell Research (CSCR), Christian Medical College
  • 90. Century Therapeutics
  • 91. Cesca Therapeutics
  • 92. CHA Biolab
  • 93. Chart Industries
  • 94. Children's GMP, St. Jude Children's Research Hospital
  • 95. China Regenerative Medicine International
  • 96. City of Hope
  • 97. Clean Cells
  • 98. Clinical Biomanufacturing Facility, University of Oxford
  • 99. Clinical Cell and Vaccine Production Facility (CVPF)
  • 100. CMIC
  • 101. CO.DON
  • 102. Cogent Biosciences
  • 103. Cognate BioServices
  • 104. CoImmune
  • 105. Comprehensive Cell Solutions (a division of New York Blood Center)
  • 106. Connell and O'Reilly Families Cell Manipulation Core Facility, Dana-Farber / Harvard Cancer Center
  • 107. Cook MyoSite
  • 108. Creative Biolabs
  • 109. CRISPR Therapeutics
  • 110. Cryoport
  • 111. CSIRO
  • 112. CTM CRC
  • 113. CureCell
  • 114. Cytopeutics
  • 115. CytoSen Therapeutics (Acquired by Kiadis Pharma)
  • 116. Daiichi Sankyo
  • 117. David and Etta Jonas Center for Cellular Therapy, UChicago Medicine
  • 118. DCPrime
  • 119. Dendreon
  • 120. ElevateBio
  • 121. Emory Cellular and Immunotherapy Core (formerly known as Emory Personalized Immunotherapy Core)
  • 122. EUFETS
  • 123. ExCellThera
  • 124. Fate Therapeutics
  • 125. Formula Pharmaceuticals
  • 126. Fosun Pharma
  • 127. Fraunhofer Institute for Cell Therapy and Immunology
  • 128. Froceth
  • 129. FUJIFILM Cellular Dynamics
  • 130. Gamida Cell
  • 131. Gates Biomanufacturing Facility
  • 132. GC Cell (Previously known as Green Cross Cell)
  • 133. GE Healthcare Life Sciences
  • 134. GenCure
  • 135. Gene and Cell Therapy Lab, Institute of Translational Health Sciences
  • 136. GenIbet Biopharmaceuticals
  • 137. Ghent University
  • 138. Gilead Sciences
  • 139. Glycostem Therapeutics
  • 140. Glycotope
  • 141. Gracell Biotechnologies
  • 142. Great Ormond Street Hospital, University College of London
  • 143. Green Cross LabCell
  • 144. GSK
  • 145. GX Acquisition
  • 146. Harvard University Stem Cell Institute
  • 147. Health Sciences Authority
  • 148. Hebei Senlang Biotechnology
  • 149. Hemostemix
  • 150. Histocell
  • 151. Hitachi Chemical
  • 152. Holostem Terapie Avanzate
  • 153. Human Cellular Therapy Laboratory, Mayo Clinic
  • 154. Immuneel Therapeutics
  • 155. Immunomic Therapeutics
  • 156. Immunovative Therapies
  • 157. IncoCell Tianjin (a wholly owned subsidiary of Boyalife)
  • 158. Indapta Therapeutics
  • 159. Innovative Cellular Therapeutics
  • 160. Instil Bio
  • 161. Interdisciplinary Stem Cell Institute, Miller School of Medicine, University of Miami
  • 162. International Stem Cell Corporation
  • 163. Invetech
  • 164. Iovance Biotherapeutics
  • 165. IsoPlexis
  • 166. Ixaka (formerly known as Rexgenero)
  • 167. Janssen Pharmaceuticals
  • 168. Japan Tissue Engineering
  • 169. Jiuzhitang Maker Cell Technology
  • 170. John Goldman Centre for Cellular Therapy, Imperial College London
  • 171. Juno Therapeutics
  • 172. JW CreaGene
  • 173. JW Therapeutics
  • 174. Kadimastem
  • 175. Kangstem Biotech
  • 176. KBI Biopharma
  • 177. Kemwell Biopharma
  • 178. Kiadis Pharma
  • 179. King's Clinical Research Facility
  • 180. Kite Pharma (acquired by Gilead Sciences)
  • 181. Krembil Cell Facility, St. Michael's Hospital
  • 182. KSQ Therapeutics
  • 183. Laboratory for Cell and Gene Medicine, University of Stanford
  • 184. Legend Biotech (A subsidiary of GenScript Biotech)
  • 185. Lineage Cell Therapeutics
  • 186. Lion TCR
  • 187. Longeveron
  • 188. Lonza
  • 189. Lyell Immunopharma
  • 190. Lykan Bioscience
  • 191. Lymphotec
  • 192. Marker Therapeutics
  • 193. Massachusetts General Hospital
  • 194. MaSTherCell
  • 195. MaxiVAX
  • 196. MD Anderson Cancer Center
  • 197. Medeor Therapeutics
  • 198. Medigene
  • 199. MEDINET
  • 200. MEDIPOST
  • 201. Merck
  • 202. Mesoblast
  • 203. Michael G. Harris Cell Therapy & Cell Engineering Facility, Memorial Sloan Kettering
  • 204. Midwest Stem Cell Therapy Center, University of Kansas Medical Center
  • 205. Miltenyi Biotec
  • 206. Minaris Regenerative Medicine
  • 207. Minovia Therapeutics
  • 208. Molecular and Cellular Therapeutics, University of Minnesota
  • 209. MolMed
  • 210. Mustang Bio
  • 211. National Eye Institute
  • 212. Ncardia
  • 213. Neon Therapeutics
  • 214. NeoProgen
  • 215. Netherlands Cancer Institute (NKI)
  • 216. New Jersey Innovation Institute (NJII)
  • 217. Newcastle Advanced Therapies
  • 218. NHS Blood and Transplant
  • 219. NIHR Guy's and St Thomas' Clinical Research Facility
  • 220. Nikon CeLL innovation
  • 221. Nipro
  • 222. Nkarta
  • 223. NKGen Biotech (formerly known as NKMax America)
  • 224. Nohla Therapeutics
  • 225. Noile-Immune Biotech
  • 226. Northwest Biotherapeutics
  • 227. Novadip Biosciences
  • 228. Novartis
  • 229. Novex Innovations
  • 230. Novo Nordisk
  • 231. Octane Biotech
  • 232. Ology Bioservices
  • 233. Ontario Institute for Regenerative Medicine
  • 234. Opexa Therapeutics
  • 235. Orca Bio
  • 236. OrganaBio
  • 237. Orgenesis
  • 238. Ori Biotech
  • 239. Overland Pharmaceuticals
  • 240. PersonGen BioTherapeutics
  • 241. Pfizer
  • 242. PharmaBio
  • 243. PharmaCell
  • 244. pHion Therapeutics
  • 245. Pluristem Therapeutics
  • 246. Precision BioSciences
  • 247. Promethera Biosciences
  • 248. Provia Laboratories
  • 249. Q-GEN Cell Therapeutics
  • 250. Rayne Cell Therapy Suite, King's College London
  • 251. Regenerative Medicine Center, Utrecht University
  • 252. Regeneus
  • 253. ReNeuron
  • 254. Research and Development Center for Cell Therapy, Foundation for Biomedical Research and Innovation
  • 255. Riyadh Pharma
  • 256. Robertson Clinical and Translational Cell Therapy, Duke University
  • 257. RoosterBio
  • 258. Roslin Cell Therapies
  • 259. Rubius Therapeutics
  • 260. S.Biomedics
  • 261. Saint-Gobain
  • 262. SanBio
  • 263. Sangamo Therapeutics
  • 264. Scinogy
  • 265. SCM Lifescience
  • 266. Scottish National Blood Transfusion Service
  • 267. Seneca Biopharma
  • 268. Servier
  • 269. Sheba Medical Center
  • 270. Shibuya
  • 271. Sorrento Therapeutics
  • 272. SOTIO
  • 273. S-RACMO
  • 274. Stem Cell Institute
  • 275. Stemedica Cell Technologies
  • 276. Stemmatters
  • 277. Stempeutics Research
  • 278. Sumitomo Dainippon Pharma
  • 279. Sydney Cell and Gene Therapy
  • 280. Syngen Biotech
  • 281. Takara Bio
  • 282. Takeda Pharmaceutical
  • 283. TC BioPharm
  • 284. TCR2 Therapeutics
  • 285. Terumo BCT
  • 286. Tessa Therapeutics
  • 287. The Discovery Labs Center for Breakthrough Medicines
  • 288. The Ottawa Hospital Research Institute
  • 289. The Philip S. Orsino Facility for Cell Therapy, Princess Margaret Hospital
  • 290. TheraCell Advanced Biotechnology
  • 291. Therapeutic Cell Production Core, Seattle Children's Research Institute
  • 292. Therapeutic Cell Production Facility, Roswell Park Comprehensive Cancer Center
  • 293. Thermo Fisher Scientific
  • 294. ThermoGenesis
  • 295. TiGenix
  • 296. T-knife
  • 297. Tmunity Therapeutics
  • 298. TrakCel
  • 299. TreeFrog Therapeutics
  • 300. Triumvira Immunologics
  • 301. Trizell
  • 302. TVAX Biomedical
  • 303. TxCell
  • 304. UC Davis GMP Laboratory
  • 305. UCLA Human Gene and Cell Therapy
  • 306. Universal Cells
  • 307. University Hospital Basel
  • 308. University of North Carolina Lineberger Comprehensive Cancer Center
  • 309. University of Wisconsin's Program for Advanced Cell Therapy
  • 310. UofR Cell Therapy Manufacturing Facility (UofR- CTMF)
  • 311. Vecura, Karolinska University Hospital
  • 312. Vericel
  • 313. VetStem Biopharma
  • 314. Vineti
  • 315. Viscofan BioEngineering (A business unit of Viscofan)
  • 316. Waisman Biomanufacturing
  • 317. West Biotherapy
  • 318. WuXi AppTec
  • 319. Zelluna Immunotherapy